

**Harvard Medical School
Curriculum Vitae**

Date Prepared: August 16, 2024

Name: Krista F. Huybrechts

Office Address: Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital
1620 Tremont Street, Suite 3030
Boston, MA 02120

Home Address: 14 Riverside Avenue
Concord, MA 01742

Work Phone: (617) 278-0933

Work Email: khuybrechts@bwh.harvard.edu

Work Fax: (617) 232-8602

Place of Birth: Wilrijk, Belgium

Education

1988	BS (<i>cum laude</i>)	Applied Economics	University of Antwerp, Antwerp, Belgium
1990	MS (<i>magna cum laude</i>)	Applied Economics - Finance	University of Antwerp
2010	PhD	Epidemiology (Thesis Advisor: Kenneth J. Rothman)	Boston University School of Public Health, Boston, MA

Faculty Academic Appointments

07/2010- 09/2013	Instructor	Medicine	Harvard Medical School, Boston, MA
10/2013- 01/2018	Assistant Professor	Medicine	Harvard Medical School
06/2013- 03/2021	Adjunct Assistant Professor (non-voting)	Epidemiology	Boston University School of Public Health
02/2018- 09/2018-	Associate Professor	Medicine	Harvard Medical School
	Associate Professor	Epidemiology	Harvard T.H. Chan School of Public Health, Boston, MA
04/2021-	Adjunct Associate Professor (non-voting)	Epidemiology	Boston University School of Public Health

Appointments at Hospitals/Affiliated Institutions

11/2009-	Project Manager	Pharmacoepidemiology &	Brigham and Women's
----------	-----------------	------------------------	---------------------

01/2010		Pharmacoeconomics	Hospital, Boston, MA
02/2010-	Research Associate	Pharmacoepidemiology &	Brigham and Women's
06/2010		Pharmacoeconomics	Hospital
07/2010-	Associate Epidemiologist	Pharmacoepidemiology & Pharmacoeconomics	Brigham and Women's Hospital

Other Professional Positions

1990-91	Health Economics Research Assistant	Center for Economic and Social Research, University of Antwerp
1991-97	Manager, International Outcomes Research	Janssen Pharmaceutica N.V., Beerse, Belgium
1997-07	Senior Researcher	Caro Research Inc., Concord, MA
2007-10	Research Scientist	United BioSource Corporation, Lexington, MA

Major Administrative Leadership Positions

2013	Organizer, 4-credit Pharmacoepidemiology course for graduate students	Boston University School of Public Health
2014-21	Associate Director of Research Administration	Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital
2018-	Director of the Harvard Program in Perinatal and Pediatric Pharmacoepidemiology (H4P)	Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital
2021-	Senior Director of Research Operations	Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital

Committee Service

Local

2018-19	Faculty Development Strategic Planning Subcommittee	Brigham and Women's Hospital
2019-20	Faculty Departure Program Working Groups	Brigham and Women's Hospital
2019-	Admissions Committee, Pharmacoepidemiology	Harvard T.H. Chan School of Public Health
2021, 2023	Chair, Biostatistics Faculty Search Committee	Brigham and Women's Hospital
2021-	Faculty Development-Faculty Affairs Strategic Planning Implementation Committee	Brigham and Women's Hospital
2021-	BWH Peer Supporter	Brigham and Women's Hospital
2023	Member, Pharmacoepidemiology Faculty Search Committee	Harvard T.H. Chan School of Public Health

Regional

2016-17	Doctoral research committee member Kathryn McInerney	Boston University School of Public Health
---------	---	---

2016-19	Doctoral research committee member John Rippolone	Boston University School of Public Health
2017-22	Doctoral research committee member Daina Esposito	Boston University School of Public Health
2020	Postpartum Depression Workgroup	Massachusetts Department of Public Health, Boston, MA
2021-2023	Doctoral research committee member Jennifer Yland	Boston University School of Public Health

National

2019-22	Data Safety Monitoring Board for the Patient-Centered Outcomes Research Institute (PCORI)-funded study “Comparative Effectiveness of Pharmacogenomics for Treatment of Depression (CEPIO-D)”	Massachusetts General Hospital, Boston, MA (coordinating center)
2021-	U.S Food and Drug Administration (FDA) Drug Safety and Risk Management (DSaRM) Advisory Committee	FDA, Silver Spring, MD
2022-23	Chair, Data Safety Monitoring Board for the NICHD-funded study “Endeavor to Stop Nausea and Vomiting Associated with Pregnancy (E-SNAP)”	Northwestern University Feinberg School of Medicine, Chicago, IL

Professional Societies

1999	International Health Economics Association 1999	Abstract Selection Committee
1999-2010	International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2000-2005 2004	Abstract Selection Committee Judge, Poster Presentations
2011-	International Society for Pharmacoepidemiology 2011-	Reviewer of abstracts submitted to Annual Conference
	2014- 2015	Core Scientific Program Committee Chair, Scientific Program Committee for the Society’s annual international meeting
	2015-	Teaching Faculty: Modern Pregnancy Pharmacoepidemiology Course
	2016	Organizer, Keynote Address “Representative Sampling in Pharmacoepidemiology: A Hot Topic or Hot Air?”
	2017-20 2017 2018-20	Executive Committee Vice President Finance Elect Vice President Finance

	2019-20	Strategic Planning Committee
	2020-	Finance Committee
2022-	Marcé of North America (Perinatal Mental Health Society)	
	2022-2023	Member of abstract committee for 2023 bi-annual meeting
	2022-	Treasurer; serving on the Executive Committee and Board

Grant Review Activities

2017, 2018	Mental Health Services Research Committee	National Institutes of Health (NIH) <i>Ad hoc</i> member
2018, 2020	Special Emphasis Panel for Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics	NIH <i>Ad hoc</i> member
2019	HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study	NIH Reviewer
2022, 2023	Review applications submitted under the Junior and Senior Postdoctoral Fellowship call	The European Science Foundation (www.esf.org) on behalf of The Research Foundation – Flanders (FWO) (Belgium) Assistance Publique – Hôpitaux de Paris (AP-HP) (France)
2021	Expert reviewer	ZonMw (the Netherlands)
2018, 2020, 2023	Reviewer for the Vidi-programme, which promotes innovation in the academic research field	
2023	External expert reviewer for submissions to the Antiepileptic Programme 2023, organized by the French Ministry of Health and Prevention	Institut pour la Recherche en Santé Publique (IReSP)
2023	Special Emphasis Panel for Rapid Translation of Epidemiological Findings into Interventions to Prevent Substance Use and Addiction	NIH <i>Ad hoc</i> member
2024	Special Emphasis Panel for Helping to End Addiction Long-term (HEAL) Initiative: Outcomes of Babies with Opioid Exposure (OBOE) consortium	NIH Reviewer

Editorial Activities

***Ad hoc* Reviewer**

Annals of Epidemiology
Annals of Internal Medicine
Annals of Medicine
BMC Psychiatry
British Journal of Clinical Pharmacology
British Medical Journal

British Medical Journal Quality & Safety
Canadian Medical Association Journal
CNS Drugs
Epidemiology
Health Policy
International Journal of Geriatric Psychiatry
JAMA
JAMA Pediatrics
JAMA Psychiatry
Journal of Clinical Epidemiology
Journal of Clinical Psychiatry
Journal of Women's Health
Medical Care
Medical Principles and Practice
Medicare & Medicaid Research Review
New England Journal of Medicine
Pediatric and Perinatal Epidemiology
Pharmacoepidemiology and Drug Safety
PLOS ONE
Value in Health

Other Editorial Roles

2018-	Associate Editor	<i>Pharmacoepidemiology and Drug Safety</i>
04/2024-	Editorial Board member	<i>JAMA Psychiatry</i>

Honors and Prizes

1990	Dr. Paul Janssen Health Economics Prize	Belgian Association of Health Economists	Best Master's thesis in the field of Health Economics
2010	School of Public Health Dean's Award	Boston University School of Public Health	Best public health research project presented at Science and Engineering Day
2010	Best Student Drug Utilization Abstract	International Society for Pharmacoepidemiology	Best student abstract submitted to the 26 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
2011	Induction in Delta Omega (Alpha Beta chapter)	Honorary Society in Public Health	Academic achievement as a graduating student
2013	2012 Mitchell B. Balter Award	<i>Journal of Clinical Psychopharmacology</i>	Best pharmaco-epidemiology article of the year
2013	Best Poster	International Society for Pharmacoepidemiology	Best poster presentation in the category "Comparative

			Effectiveness Research” submitted to the 29 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
2013	Reviewer recognition	<i>Pharmacoepidemiology and Drug Safety, Journal of Clinical Epidemiology</i>	Recognition for high quality of peer reviews
2014	Reviewer recognition	<i>Canadian Medical Association Journal</i>	Recognition for high quality of peer reviews
2015	Top 10 Clinical Research Achievement Award	Clinical Research Forum	Awarded to ten best clinical research publications in 2015
2016	2016 DOM Early Career Faculty Mentoring Award	Department of Medicine, Brigham and Women’s Hospital	Awarded in recognition of commitment to mentoring faculty and fellows in the Department of Medicine
2016	Fellow of the International Society for Pharmacoepidemiology (FISPE)	International Society for Pharmacoepidemiology	Fellowship awarded in recognition of substantial scholarship, leadership role in the Society, and leadership in the discipline of pharmacoepidemiology
2016	Reviewer recognition	<i>Canadian Medical Association Journal</i>	Recognition for high quality of peer reviews
2017	Reviewer recognition	<i>Annals of Internal Medicine</i>	Recognition for high quality of peer reviews
2019-2020	Brigham Leadership Program	Brigham and Women’s Hospital	Selected as a member of the 2019-2020 cohort of the Brigham Leadership Program
2022	Innovator Award Finalist	Society for Birth Defects Research and Prevention	Conference abstract on “Classification of Congenital Malformations Informed by Machine Learning with Human Adjudication” selected for Innovator Award Competition at 2022 Annual Meeting
2022	Thesis Mentor Award	Harvard T.H. Chan School of Public Health	Awarded in recognition of mentorship provided in support of thesis
2023	Innovator Award	Society for Birth Defects Research and Prevention	Conference presentation on “Screening for Elevated Congenital Malformation Risk Following Prenatal

			Antipsychotic Exposure Using Tree-Based Scan Statistics for Signal Identification” recognized with Innovator Award at 2023 Annual Meeting
2023	Outstanding Faculty Service Award	Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital	Awarded in recognition of distinguished service and leadership
2023	MONA Medal for Research	Marcé of North America (MONA)	Awarded in recognition of groundbreaking research supporting the aims of the Society
2024	Top Reviewer recognition	<i>JAMA Psychiatry</i>	Among top 4% of reviewers based on quality and timeliness of reviews in 2023

Report of Funded and Unfunded Projects

Funding Information

Past

2008-11	Comparative Safety and Effectiveness of Antipsychotics Agency for Healthcare Research and Quality (AHRQ) U18-HS017918 Co-Investigator (PI: Stephen Crystal) The study objective was to evaluate the outcomes of individual antipsychotic medications in elderly residents of nursing homes, with a focus on all-cause mortality, and clinical outcomes including myocardial infarction, stroke, serious bacterial infections, and hip fracture. I assumed primary responsibility for the subcontract.
2009-14	Comparative Effectiveness and Safety of Depression Treatments During Pregnancy AHRQ R01-HS018533 Site PI (PI: Sonia Hernandez-Diaz) The primary objective was to generate evidence on the outcomes of treatments to manage depression in low-income pregnant women and their children.
2011-12	Instrumental variable analysis for comparative effectiveness studies in nursing home populations: validity of instruments based on nursing home prescribing preferences (Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Methods Center) AHRQ HHSA-290-2005-00161 Project PI (PI: Sebastian Schneeweiss) The primary objective was to identify and test different potential instrumental variables based on nursing home prescribing patterns for use in comparative effectiveness studies in these settings.
2012-17	Comparative Effectiveness of Oral Anticoagulants Boehringer Ingelheim GmbH Co-Investigator (PI: Sebastian Schneeweiss)

- The study objective was to quantify the relationship between anticoagulant use (warfarin, dabigatran and other newer oral anticoagulants) and the occurrence of major thromboembolic events, major bleeding events, hepatotoxicity, and all-cause mortality in patients with non-valvular atrial fibrillation.
- 2013-18 Improved Methods to Assess the Comparative Safety of New Psychiatric Medications
NIH/National Institute of Mental Health (NIMH) K01 MH099141
Principal Investigator
The study objective was to develop, adapt and rigorously validate different approaches for near-real-time monitoring of new psychiatric drugs and to develop methods to address confounding and outcome misclassification, with particular attention to the methodological issues arising from the needs and circumstances of people with mental illness.
- 2014-17 Comparative Safety of commonly prescribed Psychotropic Drugs in pregnant Women
NIH/NIMH: R01 MH100216
Site-PI – effort subsumed under K01 award (PI: Sonia Hernandez-Diaz)
The study objective was to quantify the outcomes of alternative approaches to manage mental disorders during pregnancy; in particular to compare clinical events following the use of specific anticonvulsants/mood stabilizers, antipsychotics, and stimulants, to assess clinical events that follow continuing versus discontinuing these drugs during pregnancy.
- 2016-17 Using Claims Data to Define Opioid Misuse and Abuse
Pfizer Inc.
Co-Investigator (PI: Brian Bateman)
The study objective was to assess the validity of claims-based algorithms to identify patients with potential opioid misuse/abuse based on opioid filling patterns and to validate these algorithms with outcomes of physician-diagnosed opioid abuse or overdose.
- 2016-17 Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Albiglutide during Pregnancy
GlaxoSmithKline
Co-Investigator (PI: Sonia Hernandez-Diaz)
The study objective was to determine whether exposure to albiglutide during pregnancy is associated with an increased risk of pre-specified adverse maternal and fetal outcomes.
- 2016-18 Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine
Eli Lilly and Company
Principal Investigator
The study objective was to evaluate maternal and fetal/infant outcomes associated with exposure to duloxetine; part of fulfillment of a Food and Drug Administration requirement for post-marketing surveillance.
- 2017-19 Ondansetron and risk of congenital malformations
NIH/National Institute of Child Health and Human Development (NICHD) R03 HD091699
Principal Investigator
The study objective was to evaluate the risk of congenital heart defects and cleft palate associated with ondansetron use during pregnancy in a national cohort we developed of 1.6 million pregnancies covered by Medicaid.
- 2017-19 International Pooling Project to Study the Safety of Drugs in Pregnancy
NIH/NICHD R21 HD092879
Site-PI (PI: Sonia Hernandez-Diaz)
The study objective was to develop an international collaboration to study the safety of

drugs in pregnancy. By pooling health care information from large population-based databases in the Nordic Countries and the United States, we were able to identify global nested exposed pregnancy cohorts to study *in utero* exposure to individual drugs in relation to rare outcomes such as specific birth defects.

- 2017-21 The Impact of Prescription Opioid Use on Pregnancy Outcomes
NIH/National Institute on Drug Abuse (NIDA) R01 DA044293
Co-Investigator (PI: Brian Bateman)
The study objective was to evaluate the association between prescription opioid exposure during the etiologically relevant pregnancy window and a variety of important adverse pregnancy outcomes previously hypothesized to be associated with such exposure. We also assessed for the outcomes in relation to specific opioids and the impact of duration of exposure and dose.
- 2017-21 Developing the capability of using national Medicaid data for FDA post-marketing surveillance to assess medication safety during pregnancy
US Food and Drug Administration HHSF223201400043I
Principal Investigator
The project aim was to develop technical capabilities for using electronic national Medicaid data in FDA post-marketing active surveillance to evaluate safety concerns raised by case reports, case series, or pregnancy registries. The focus was on developing and validating Medicaid-specific algorithms to estimate gestational age for live and non-live births, and to develop analytic tools to assess the impact on relative risk estimates of misclassification, selection bias and confounding.
- 2020 Observational Studies to Assess Maternal and Fetal Outcomes Following Exposure to Duloxetine: Sensitivity Analyses – addendum to original study
Eli Lilly and Company
Principal Investigator
To conduct sensitivity analyses to supplement the original evaluation of the maternal and fetal/infant outcomes associated with exposure to duloxetine.
- 2020-21 The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy: Administrative supplement focused on maternal mortality
NIH/NIDA R01 DA049822 – administrative supplement
MPI (MPI: Brian Bateman)
The study objective was to describe the timing and risk factors for postpartum maternal deaths attributable to drug overdose.
- 2021-22 Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab for Treatment of Psoriasis during Pregnancy – protocol and statistical analysis plan development
UCB Biopharma SRL
Principal Investigator
The study objective was to develop a protocol and statistical analysis plan to evaluate the safety of bimekizumab during pregnancy to fulfill the post-marketing surveillance requirement from the European Medicines Agency.
- 2018-23 In-utero Exposure to Psychotropic Medications and the Risk of Neurodevelopmental Disorders
NIH/NIMH R01 MH116194
Principal Investigator
The study objective is to evaluate the risk of neurodevelopmental disorders following *in*

- utero* exposure to mood stabilizers and other anticonvulsants, antidepressants, antipsychotics, and stimulants.
- 2022-23 Maternal and infant characteristics and outcomes following exposure to HyQvia during pregnancy: a case series study based on US claims data
Takeda
Principal Investigator
The objective is to describe the frequency of adverse pregnancy outcomes in a series of patients exposed to HyQvia during pregnancy.
- Current**
- 2019-24 Comparative Safety of Non-Insulin Agents in Pregnant Women with Pregestational Diabetes
NIH/NICHD R01 HD097778
Co-Investigator (PI: Sonia Hernandez-Diaz)
The objective of this project is to evaluate the comparative risks and benefits of non-insulin therapies in a large cohort of pregnant women and their infants.
- 2019-24 Randomized cardiovascular trials duplicated using prospective longitudinal insurance claims: applying techniques of epidemiology (RCT DUPLICATE)
NIH/National Heart, Lung, and Blood Institute R01 HL141505
Co-Investigator (PI: Jessica Franklin)
The purpose of this project is to empirically evaluate the validity of real-world health data studies by conducting a systematic replication of a large sample of randomized trials of cardiovascular outcomes to ensure that validity is not influenced by the availability of trial results.
- 2020-24 Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge: A Multimodal Analysis
US Food and Drug Administration
Co-Investigator (PI: Ameet Sarpatwari & Aaron Kesselheim)
The objective of this project is to evaluate how successful Risk Evaluation and Mitigation Strategy (REMS) programs have been in minimizing harm or what other impacts they have had on health care delivery.
- 2020-24 The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy
NIH/NIDA R01 DA049822
MPI (MPI: Brian Bateman) (\$1,776,707)
The goal of this study is to utilize state of the art epidemiological methods to generate unbiased or minimally biased estimates of the comparative safety and effectiveness of medications used to treat OUD in pregnancy.
- 2020-24 Identification of Novel Agents to Treat PTSD using Clinical Data
NIH/NIMH R01 MH121397
Site-PI (MPIs: Brian Shiner & Jaimie Gradus) (\$101,131)
The study objective is to leverage large-scale electronic health record data to identify existing medications that may be repurposed as PTSD treatments.
- 2021-26 Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy
NIH/NICHD R01 HD104646

- 2021-26 MPI (MPI: Shirley Wang) (\$1,657,569)
 The study objective is to develop and implement TreeScan, a signal detection method, for surveillance of a broad range of potential adverse maternal, fetal and neonatal outcomes associated with antipsychotic medication use in pregnancy.
 An Expanded National Cohort Study of Transgender People
 NIH/National Institute on Aging R01 AG066956
 Co-Investigator (PI: Michael Goodman)
 The study objective is to expand and extend the ongoing longitudinal Study of Transition, Outcomes & Gender (STRONG; a cohort of transgender people identified from the electronic medical records) and to address the following areas: 1) occurrence of acute cardiovascular events in relation to hormone therapy; 2) age-related changes in mental health status and incidence of dementia among transgender people; and 3) metabolic and hematologic consequences of cross-sex hormone therapy.
- 2022-26 TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations
 NIH/NICHD R01 HD110092
 MPI (MPI: Shirley Wang) (direct costs requested: \$1,264,578)
 The study objective is to develop and test the performance of tree-based scan statistic (TreeScan) approaches for the systematic and simultaneous evaluation of multiple potential adverse outcomes in pediatric populations, and to implement these methods for prospective sequential surveillance of new pediatric medications.
- 2022-27 Safety of Benzodiazepines and Non-Benzodiazepine Sedative Hypnotics in Pregnancy
 NIH/NICHD R01 HD107772
 MPI (MPI: Brian Bateman) (\$2,069,253)
 The study objective is to evaluate the safety of benzodiazepines and non-benzodiazepine sedative hypnotics during pregnancy considering a broad range of clinically relevant adverse pregnancy outcomes.
- 2022-27 Comparative Safety of Antibiotics for Common Bacterial Infections During Pregnancy
 NIH/NICHD R01 HD107759
 Co-Investigator (PI: Yanmin Zhu)
 The study objective is to evaluate the comparative safety of antibiotics commonly used for the treatment of bacterial infections during pregnancy.
- 2023-2028 A national study on the effects of air pollution and temperature on children's neurodevelopmental outcomes
 NIH/National Institute of Environmental Health Science R01 ES034038
 Site-PI (PI: Stefania Papatheodorou) (direct costs requested: \$464,466)
 The study objective is to investigate the independent and joint effects of prenatal and early childhood exposure to PM_{2.5} and chemical components, NO₂, O₃, temperature and SES in two national longitudinal pregnancy- newborn cohorts followed up until the age of 8.
- 2023-2033 Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab for Treatment of Psoriasis during Pregnancy – study execution
 UCB Biopharma SRL
 Principal Investigator (\$1,763,945)
 The goal of this study is to prospectively monitor the safety of bimekizumab during pregnancy over a 10-year time period to fulfill the post-marketing surveillance requirement from the European Medicines Agency.

2024-2025 Clinically Recognized Congenital Cytomegalovirus Infection and Risk of Long-Term Neurologic and Non-neurologic Complications: Evidence from a Nationwide Cohort
NIH/NIAID R03
Co-Investigator (PI: Yanmin Zhu)
The study objective is to provide a comprehensive assessment of the long-term sequelae of congenital cytomegalovirus infection.

Report of Local Teaching and Training

Teaching of Students in Courses

Boston University School of Public Health Courses

2013, 2015, 2017, 2019	Pharmacoepidemiology Epidemiology graduate students	Boston University School of Public Health Instructor, 4 credit course (3-hr lecture/weekly/14 weeks)
---------------------------	--	---

HMS/HSDM/DMS Courses

2013, 2014, 2016, 2018, 2019, 2023	Translational Pharmacology: Pharmaco-epidemiology, pharmaco-economics, and pharmaco-vigilance (ME733.0)	HMS 3-hr case study session (all years, except 2023) One 2-hr and two 1-hr lectures (2019) 1-hr consultation course assignment and grading (2023)
	Graduate students and post-graduate MDs	
2015, 2016	Translational Medicine: Unmet Medical Needs and Translational Solutions HMS TransMed Course (BCMP 311qc) Serves MD, MD/PhD, and PhD students from Harvard Medical School, Harvard University, and MIT, and MD students and fellows from other US and international institutions	HMS 3.5-hr lecture
2015, 2016, 2017, 2019	T3/T4 Research: Translating Effective Interventions into Practice Part of the Harvard Clinical and Translational Science Center (Catalyst) Postgraduate Education Program in Clinical and Translational Science	HMS 1-hr lecture
2016, 2017	Introduction to Comparative Effectiveness Research (on-line course) Part of the Harvard Catalyst Postgraduate Education Program in Clinical and Translational Science	HMS 1-hr lecture

2019, 2020	Clinical Data Science Program: Large claims databases for pregnancy research (Master's in Clinical Investigation)	HMS 2-hr lecture
2020, 2021, 2022	Essentials of the Profession: Clinical Epidemiology and Population Health	HMS Four 2-hr small group sessions (2020); eight 2-hr small group sessions (2021, 2022)
2020, 2021, 2022, 2023	Advanced Integrated Science (AISC) 624.0: Medications and Evidence	HMS 1-hr journal club (2020, 2021, 2022, 2023); 1-hr lecture (2021, 2022, 2023)

Harvard T.H. Chan School of Public Health Courses

2013, 2015, 2016, 2018, 2019, 2020	Advanced Pharmacoepidemiology (EPI 286) Epidemiology graduate students	HSPH 2-hr lecture
Summer 2013, 2015, 2016, 2018, 2020, 2021	Introduction to Clinical Epidemiology (EPI 208) Participants in Program in Clinical Effectiveness	HSPH Workshop faculty leader, two 2-hr sessions
2014	Health Services Research (EPI 235) Epidemiology graduate students	HSPH 1-hr lecture
2017, 2018, 2019, 2020, 2021	Pharmacoepidemiology (EPI 221) Epidemiology graduate students	HSPH 2-hr lecture
Summer 2020, 2021, 2022	Effectiveness Research with Longitudinal Healthcare Databases (EPI 253)	HSPH 1.5-hr lecture; Workshop faculty leader (two 90-min sessions)
2021-	Database Analytics in Pharmacoepidemiology (EPI 286) Epidemiology Graduate Students	HSPH, Instructor 1.5-hr lecture/2 sessions per week/8 weeks
Summer 2022, 2023, 2024	Introduction to Clinical Epidemiology (EPI 208) Participants in Program in Clinical Effectiveness	HSPH, Core faculty Two 2-hr and two 3-hr group sessions; eight 1-hr one-on-one sessions
2022	Maternal and Child Health Seminar (SBS 360) Core course for graduate students concentrating in maternal and child health	HSPH, 1-hr lecture

Laboratory and Other Research Supervisory and Training Responsibilities

2011-	Advisor for trainees and junior clinical HMS faculty on issues related to study design, data analysis and interpretation of study findings	1:1 meetings for 2 hours total per week throughout the year
-------	--	---

2014-20	Supervise team of 10 analysts	Monthly one-hour team meetings and 1 hour per week supervision project assignment
2014-	Supervise team of 12 Research Specialists	Weekly one-hour team meetings (2014-21) Monthly one-hour team meetings (2022-) 4 hours per week of direct supervision

Formally Mentored Harvard Medical, Dental and Graduate Students

2011-12	Shu-Hui Chiang, MS candidate, Harvard T.H. Chan School of Public Health Co-mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science
2011-13	Kristin Palmsten, ScD candidate, Harvard T.H. Chan School of Public Health Member of doctoral research committee; five manuscripts published; recipient of the 2013 Lilienfeld Award (Society for Epidemiologic Research) <i>Position:</i> Senior Research Investigator, HealthPartners Institute
2012-13	Sonja Swanson, ScD candidate, Harvard T.H. Chan School of Public Health Mentor on student research project to evaluate the comparative effectiveness of antidepressant medications during pregnancy; manuscript published. <i>Position:</i> Associate Professor and Principal Investigator of Causal Inference; Erasmus University, the Netherlands
2013-16	Yoonyoung Park, ScD candidate, Harvard T.H. Chan School of Public Health Mentor on student research project to improve confounding control when evaluating the comparative safety of antipsychotic medications in the elderly; podium presentation at International Conference on Pharmaco-Epidemiology (ICPE) 2014, manuscript published. Member of doctoral research committee; recipient of 2015 ICPE Best Student Abstract (3 rd place); dissertation study selected by AJP for release during APA Annual meeting and invited to press briefing <i>Position:</i> Director, Lead Epidemiologist, Moderna
2014-16	Kathryn Rough, ScD candidate, Harvard T.H. Chan School of Public Health Mentor on student research project to describe utilization patterns and adverse events among potential aberrant opioid users; recipient of 2015 ICPE Best Student Abstract (2 nd place); manuscript on Centers for Medicare & Medicaid Services (CMS) policy to suppress drug abuse-related claims published in JAMA. <i>Position:</i> Associate Director, Epidemiology and Outcomes Research, IQVIA
2017-20	Jenny Sun, PhD candidate, Harvard T.H. Chan School of Public Health Chair of doctoral research committee <i>Position:</i> Associate Director, Epidemiology, Safety Surveillance Research, Pfizer
2018-20	Katrina Mott, PhD candidate, Harvard T.H. Chan School of Public Health Member of doctoral research committee <i>Position:</i> Associate Principal Scientist, Pharmacoepidemiology Database Research

	Unit, Merck
2018-21	Alejandro Szmulewicz, PhD candidate, Harvard T.H. Chan School of Public Health Mentor on student research projects to evaluate the interaction between opioids and CNS depressant drugs and the risk of overdose <i>Position:</i> Postdoctoral scientist at Harvard T.H. Chan School of Public Health
2019-20	Kathleen Tang, MS Candidate, Harvard T.H. Chan School of Public Health Mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science <i>Position:</i> Research Analyst, Sentinel Initiative at Harvard Pilgrim Health Care Institute
2021-2022	Sonia Kim, MS Candidate, Harvard T.H. Chan School of Public Health Mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science <i>Position:</i> Scientist at Genesis Research Epidemiology
2022-2023	Motohiko Adomi, MS Candidate, Harvard T.H. Chan School of Public Health Mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science (recipient 2023 Rose Traveling Fellowship Program at Harvard T.H. Chan School of Public Health; recipient Best Thesis topic award at Thesis Symposium)
2022-2023	Christopher Tanski, MPH Candidate, Harvard T.H. Chan School of Public Health Practicum mentor
2022-2023	Ramona Wu, MS Candidate, Harvard T.H. Chan School of Public Health Academic advisor and mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science
2023-	Motohiko Adomi, PhD Candidate, Harvard T.H. Chan School of Public Health Academic advisor and thesis mentor
2024-	Zoey Ning, MS Candidate, Harvard T.H. Chan School of Public Health Mentor of thesis in partial fulfillment of the requirements for the degree of Master of Science

Other Mentored Trainees and Faculty

2013-15	Rishi Desai, PhD, Assistant Professor of Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics, HMS <i>Career stage:</i> postdoctoral research fellow. <i>Mentoring role:</i> mentor. <i>Accomplishments:</i> eight manuscripts published together, promoted to faculty.
2014-	Shirley Wang, PhD, Associate Professor of Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics, HMS <i>Career stage:</i> junior faculty. <i>Mentoring role:</i> career development and other mentoring support, involving weekly meetings. <i>Accomplishments:</i> established a methods core working group within the division of pharmacoepidemiology, successfully submitted two grants together.
2016-18	Anna Cantarutti, PhD, Assistant Professor, Università degli Studi di Milano-Bicocca, Milano, Italy, Università degli Studi di Milano-Bicocca, Milano <i>Career stage:</i> visiting PhD candidate; visiting Post-Doctoral Research Fellow.

- Mentoring role:* Advisor on dissertation research; Mentor on post-doctoral research studies. *Accomplishments:* completion of dissertation and post-doctoral research culminating in appointment as junior faculty at home institution.
- 2018-19 Nicole Tsao, Director, Pharmacoepidemiology, Sanofi Genzyme
Career stage: Post-Doctoral Research Fellow. *Mentoring role:* Mentor in perinatal pharmacoepidemiology. *Accomplishments:* conducted preliminary work for diabetes grant and secured position in industry.
- 2018- Yanmin Zhu, Instructor in Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics, HMS
Career stage: Post-Doctoral Research Fellow and junior faculty. *Mentoring role:* Mentor on various research studies in perinatal pharmacoepidemiology. *Accomplishments:* promoted to faculty at HMS, secured R01 funding from NICHD
- 2021- Katsiaryna Bykov, PharmD ScD, Assistant Professor of Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics, HMS
Career stage: junior faculty. *Mentoring role:* Primary Mentor on K01 Career Development Award (NIA). *Accomplishments:* track record of publishing in high impact journals and obtaining grant funding.
- 2021- Timothy Savage, MD, MPH, MSc, Instructor in Medicine, Division of Pharmacoepidemiology & Pharmacoeconomics, HMS
Career stage: junior faculty. *Mentoring role:* primary mentor, involving weekly meetings. *Accomplishments:* several ongoing research projects and awarded K23 application.
- 2022 Elizabeth Nyamwange, senior at the Illinois Math and Science Academy
Career stage: Participant in Research Science Institute summer program. *Mentoring role:* Summer project mentor. *Accomplishments:* Named a top 300 Scholar in the 82nd Regeneron Science Talent Search; the nation's oldest and most prestigious science and mathematics competition for high school seniors.
- 2022 Ariel Freedman, senior at Bates College
Career stage: DEI summer intern in the Division of Pharmacoepidemiology and Pharmacoeconomics. *Mentoring role:* Summer project mentor. *Accomplishments:* successfully completed summer internship culminating in presentation to the division. Hired as a research assistant within the Division of Pharmacoepidemiology and Pharmacoeconomics upon graduation in May 2023.
- 2022- Loreen Straub, MD MS, Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, HMS
Career stage: postdoctoral research fellow, junior faculty. *Mentoring role:* primary mentor, involving weekly meetings. *Accomplishments:* several ongoing research projects (7 first-author publications), promoted from postdoctoral research fellow to faculty position and submission of K01 application.
- 2023 Nadine Syakira, high school senior, Indonesia
Career stage: Participant in Research Science Institute summer program. *Mentoring role:* Summer project mentor. *Accomplishments:* Completed research project on Patterns of Antihypertensive Medication Use During Pregnancy in the Medicaid Population.

- 2023- Chi-Wan (Grace) Lin, Visiting Post-Doctoral Research Fellow (Taiwan)
Career stage: postdoctoral research fellow. *Mentoring role:* primary mentor, involving weekly meetings.
- 2023- Anderson Chen, MD, Instructor in Medicine, HMS, Geriatric Psychiatry Department at Massachusetts General Hospital, Harvard Medical School
Career stage: Attending geriatric psychiatrist. *Mentoring role:* Secondary mentor on HMS Dupont Warren Fellowship project.
- 2023-2024 Heidi Zakoul, MPH Candidate, Boston University School of Public Health
Career stage: Research Assistant in Division of Pharmacoepidemiology and MPH student. *Mentoring role:* Practicum mentor
- 2023- Nedghie Adrien, PhD MPH, T32 Post-Doctoral Research Fellow at Harvard T.H. Chan School of Public Health.
Career stage: postdoctoral research fellow. *Mentoring role:* mentor for research component of her training at Division of Pharmacoepidemiology and Pharmacoeconomics, HMS (primary mentor: Dr. Sonia Hernandez-Diaz, Harvard T.H. Chan School of Public Health)
- 2023-2024 Natchanika (Dao) Sinthuchai, MD, MS student at Harvard T.H. Chan School of Public Health
Career stage: MS student. *Mentoring role:* mentor for research component of her training at Division of Pharmacoepidemiology and Pharmacoeconomics, HMS (primary mentor: Dr. Sonia Hernandez-Diaz, Harvard T.H. Chan School of Public Health)
- 2023-2024 Pin-Chia (Clare) Huang, MS (Taiwan), MS student at Harvard T.H. Chan School of Public Health
Career stage: MS student. *Mentoring role:* mentor for research component of her training at Division of Pharmacoepidemiology and Pharmacoeconomics, HMS (primary mentor: Dr. Sonia Hernandez-Diaz, Harvard T.H. Chan School of Public Health)
- 2024 Ahhyung Choi, PhD, Visiting Post-Doctoral Research Fellow (South Korea)
Career stage: postdoctoral research fellow. *Mentoring role:* mentor for research component of her training at Division of Pharmacoepidemiology and Pharmacoeconomics, HMS (primary mentor: Dr. Florence Bourgeois, Harvard-MIT Center for Regulatory Science).

Local Invited Presentations

No presentations below were sponsored by outside entities

- 2011 Differential risk of death in older nursing home residents prescribed specific antipsychotic medications / Invited seminar
Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Medical Center, Boston, MA
- 2016 Antipsychotics and the risk of congenital malformation / Invited seminar
Women's Mental Health Outside Speaker Sessions, Department of Psychiatry, Brigham and Women's Hospital

- 2017 Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study / Grand Rounds
Department of Pediatrics, Cambridge Hospital, Cambridge, MA
- 2018 Using large databases to study the safety of medications in pregnancy / Perinatal Conference
Department of Obstetrics and Gynecology, BWH
- 2019 Drug Safety during Pregnancy Methods and Application: Zofran / Invited seminar
Newborn Epidemiology & Clinical Research Seminar Series, Beth Israel Deaconess Medical Center, Boston, MA
- 2019 Drug Safety during Pregnancy Methods and Application: Zofran / Grand Rounds
Department of Pediatric Newborn Medicine, BWH
- 2019 The Role of Large Administrative Databases in Pharmacoepidemiologic Research / Grand Rounds
Department of Anesthesia, BWH
- 2022 Perinatal Pharmacoepidemiology: Seeing the forest for the trees? Invited seminar
Harvard Newborn Health Services and Epidemiology Seminar series, Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA
- 2023 Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns / Invited Seminar Program in Opioid and Pain Innovation (POPI), Brigham and Women's Hospital, Boston, MA
- 2023 Understanding Medication Safety in Pregnancy: Seeing the forest for the trees / Invited
Regulatory Science Forum lecture at Harvard-MIT Center for Regulatory Science, Boston, MA
- 2023 Healthcare Databases: The opioids epidemic spills into pregnancy / Invited
16th Kolokotronis Symposium, Causal inference in pregnancy: Real world data when randomized trials are impractical, Harvard T.H. Chan School of Public Health, Boston, MA

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

No presentations below were sponsored by outside entities.

Regional

- 2009 Pharmacoepidemiology / Invited lecture
Modern Epidemiology, Department of Epidemiology, Boston University School of Public Health
- 2009, 2010 Pharmacoepidemiology / Invited lecture
Introduction to Epidemiology, Department of Epidemiology, Boston University School of Public Health
- 2010 Adverse health outcomes associated with psychotropic medication use in older nursing home patients / Invited seminar
Slone Epidemiology Center Visiting Lecturer Seminar Series, Boston, MA
- 2020 Using big data to inform big decisions regarding medication use in pregnancy: The case of ondansetron / Grand Rounds
Department of Obstetrics & Gynecology Grand Rounds & Maternity Center Town Hall.
UMass Memorial Medical Center, Worcester, MA (virtual)

National

- 2013 Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research / DEcIDE Methods Center Webinar
Agency for Healthcare Research and Quality, Bethesda, MD
- 2015 Antidepressant Use in Pregnancy and the Risk of Cardiac Defects / Plenary talk
Clinical Research Forum Annual Meeting, Washington, DC
- 2015 Design of Epidemiologic Studies to Evaluate the Impact of Selective Serotonin Reuptake Inhibitors (SSRI) Exposures during Pregnancy / Plenary talk
Second biennial Perinatal Mental Health Conference, Translational Research in Perinatal Mental Health: Laboratory to Bedside to Community Practice, Chicago, IL
- 2016 New Approaches to the Design and Analysis of Studies Evaluating Drug Safety during Pregnancy / Invited symposium
The Teratology Society 56th Annual Meeting: New Horizons in Birth Defects Research, San Antonio, TX
- 2017 Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches / Invited workshop
2017 Annual American Society of Clinical Psychopharmacology Meeting, Miami, FL
- 2018 Safety of Psychiatric Medications in Pregnancy / Psychiatry Grand Rounds
Samuel Novey Lectureship in Psychological Medicine, Johns Hopkins Department of Psychiatry and Behavioral Sciences, Baltimore, MD
- 2018 Fact or Fiction? Antidepressants Aren't Safe in Pregnancy / Invited Educational Symposium
2018 American Psychiatric Association Annual Meeting, New York, NY
- 2019 Using Big Data to Inform Big Decisions regarding Psychiatric Medication Use in Pregnancy / Keynote Address
Marcé of North America Perinatal Mental Health Conference, Chapel Hill, NC
- 2020 Contextualizing the Potential Risks of Ondansetron Use in Pregnancy / Invited seminar
Aetion, Inc., New York, NY (virtual)
- 2020 Benefit-Risk Trade-off for Psychiatric Medications in Pregnancy / Invited lecture
Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research in Women's Health organized workshop entitled "Pregnancy and Maternal Conditions that Increase Risk of Morbidity and Mortality", Bethesda, MD (virtual)
- 2020 Active Surveillance of the Safety of Medications Used in Pregnancy / Invited seminar
FDA Office of Surveillance and Epidemiology, Silver Spring, MD (virtual)
- 2021 Advanced approaches for evaluating drug safety in pregnancy / Invited seminar
FDA Sentinel Innovation and Methods Seminar series, Silver Spring, MD (virtual)
- 2022 Postpartum Opioid-Related Mortality in Medicaid Patients / Invited lecture
2022 NIH Implementing a Maternal health & PRenancy Outcomes Vision for Everyone (IMPROVE) Initiative Awardee Workshop, Bethesda, MD (virtual)
- 2022 Understanding Psychotropic Medication Safety in Pregnancy: A Mirage or the Next Frontier? / Invited lecture
The 14th Philadelphia Prenatal Conference, Philadelphia, PA (virtual)
- 2022 Methods development for pregnancy safety in Medicaid / Invited lecture
FDA Office of Surveillance and Epidemiology Safety, Silver Spring, MD (virtual)
- 2022 Understanding Psychotropic Medication Safety in Pregnancy: A Mirage or the Next Frontier? / Grand Rounds
Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, NJ (virtual)

- 2023 Understanding Psychotropic Medication Safety in Pregnancy: A Mirage or the Next Frontier? / Virginia Tarlow, M.D. Grand Rounds
Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL
- 2023 Understanding Psychotropic Medication Safety in Pregnancy: A Mirage or the Next Frontier? / Grand Rounds
Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai; New York, NY
- 2023 Invited expert panelist at the Duke-Margolis Center's public workshop "Optimizing the Use of Postapproval Pregnancy Safety Studies", organized on behalf of the US Food and Drug Administration / Public Workshop
National Press Club, Washington DC
- 2023 Understanding the Safety of Psychotropic Medications in Pregnancy: Methods and Applications / Invited Symposium
Marcé of North America Conference, Alexandria, VA
- 2024 Advancing Inclusion: Integrating Pregnant and Lactating People in Research / Invited Presentation and Roundtable Discussion
Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) Bioethics Collaborative, Boston, MA
- 2024 National Curriculum in Reproductive Psychiatry Fellows Series / Invited Expert Roundtable Discussion
NCRP / Marcé of North America, Baltimore, MD (virtual)
- 2024 Confounding Adjustment in Analyses of Psychotropic Drug Effects on Pregnancy Outcomes / Invited Lecture
Developing Brain Institute, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington DC

International

- 1995 Health Economics module of European Regulatory Affairs Course / Course leader
Institute for Pharmaceutical Business Management, the Netherlands
- 1995 Health Economics course for pharmaceutical executives / one-day course
Janssen Pharmaceutica, Jakarta, Indonesia
- 2013 Harnessing the Medicaid Analytic Extract to Evaluate Medications in Pregnancy / Invited seminar
Faculty of Pharmacy, University of Montreal, Canada
- 2015 Welcome Address, Moderator for Keynote Address (Computer Power and Human Reason: From Calculation to Judgment), Closing Remarks
31th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA
- 2015- Modern Pregnancy Pharmacoepidemiology / Instructor pre-conference course
International Conference of Pharmacoepidemiology & Therapeutic Risk Management (location changes every year)
- 2017 Effectiveness Research with Longitudinal Healthcare Databases / 1-week course (co-instructor with Dr. Sebastian Schneeweiss)
Summer School on Modern Methods in Biostatistics and Epidemiology, Treviso, Italy
- 2019 Contextualizing the Potential Risks of Ondansetron Use in Pregnancy / Invited Plenary Lecture
International Conference on Hyperemesis Gravidarum, Amsterdam, The Netherlands

- 2020 Drug treatment for ADHD during pregnancy / Invited lecture
ADHD Network. ADHD and Lifestyle, Utrecht, the Netherlands (Due to a schedule conflict, the presentation was delivered by my co-author, Dr. Johan Reutfors, Associate Professor of Psychiatry and Clinical Psychiatrist at Karolinska Institutet, Sweden)
- 2020 When one turns to two: The example of drugs during pregnancy
Course on Register-based research: Pharmacoepidemiology / Invited speaker
Nordforsk, Oslo, Norway (virtual)
- 2020 Meta-analysis of observational studies
Course on Register-based research: Pharmacoepidemiology / Invited speaker
Nordforsk, Oslo, Norway (virtual)
- 2021 Using Big Data to Inform Big Decisions regarding Medication Use in Pregnancy / Invited speaker
9th edition of the Bordeaux PharmacoEpidemiology Festival, Bordeaux, France (virtual)
- 2022 Global Challenges and Opportunities in Evaluating Peri-pregnancy Exposure and Safety Risks Through Database Studies / Invited speaker
DIA Global Pharmacovigilance and Risk Management Strategies Conference, Baltimore, MD (virtual)
- 2022 Association between SARS-CoV-2 Infection during Pregnancy and Postpartum Depression and Anxiety: Finding from the International Registry of Coronavirus Exposure in Pregnancy (IRCEP) Study / Invited seminar
StressGene Research Group: University of Iceland/ Karolinska Institute, Reykjavík, Iceland (virtual)
- 2022 In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders / Invited seminar
Centre of Research Excellence in Medicines Intelligence: UNSW Sydney and nationwide pharmacoepi network, Sydney, Australia (virtual)
- 2022 Perinatal pharmacoepidemiology - Seeing the forest for the trees / Invited symposium speaker
International Marcé Society Conference, London, UK
- 2023 Registries Aren't Always the Answer: Novel Designs for Executing Post-Market Pregnancy Requirements/ Invited speaker
DIA 2023 Global Annual Meeting, Boston, MA
- 2024 Multinational Registry Studies on Drugs in Pregnancy: Challenges and Perspectives / Invited Speaker
Joint OTIS-ENTIS Meeting, Nyborg, Denmark
- 2024 Target Trial Emulation for Interventions in Pregnancy / Invited Workshop and Symposium
UNSW Sydney and Prince of Wales Hospital, Sydney, Australia
- 2024 Conceptual foundations of epidemiologic study design and analysis / Invited Course
Faculty (weeklong course)
University of Bergen, Bergen, Norway

Report of Scholarship

ORCID: <https://orcid.org/0000-0001-5805-8430>

†corresponding author

Peer reviewed publications in print or other media

Research investigations

1. Cookson RF, **Huybrechts KF**. Risperidone: An assessment of its economic benefits in the treatment of schizophrenia. *J Med Econ*. 1998;1:103-34.
2. Caro JJ, **Huybrechts KF**, for the Stroke Economic Analysis Group. Stroke treatment economic model (STEM): Predicting long-term costs from functional status. *Stroke*. 1999;30:2574-9.
3. Caro JJ, **Huybrechts KF**, Duchesne I. Management patterns and costs of acute ischemic stroke. An international study. *Stroke*. 2000;31:582-90.
4. Caro JJ, **Huybrechts KF**, De Backer G, De Bacquer D, Closon MC, for the WOSCOPS Economic Analysis Group. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. *Acta Cardiol*. 2000;55(4):239-46.
5. Caro JJ, **Huybrechts KF**, Kelley H, for the Stroke Economic Analysis Group. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction. *Stroke*. 2001;32(1):100-6.
6. Caro JJ, **Huybrechts KF**, Klittich WS. Secondary prevention fallacy: Pitfalls in comparing with primary. *Expert Rev Pharmacoecon Outcomes Res*. 2001;1(1):13-8.
7. Payne KA, **Huybrechts KF**, Caro JJ, Craig Green TJ, Klittich WS. Long term cost-of-illness in stroke. An international Review. *Pharmacoeconomics*. 2002;20(12):813-25.
8. Caro JJ, Ward A, Green TC, **Huybrechts K**, Arana A, Wait S, Eleftheriou A. Impact of thalassemia major on patients and their families. *Acta Haematol*. 2002;107(3):150-7.
9. Ward A, Caro JJ, Green T, **Huybrechts K**, Arana A, Wait S, Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. *BMC Clin Pharmacol*. 2002;2(1):3.
10. Caro JJ, **Huybrechts KF**, Craig Green TJ. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: A systematic review. *BMC Blood Disorders*. 2002;2(1):4.
11. Caro JJ, **Huybrechts KF**, Klittich WS, Jackson JJ, McGuire A, for the CORE Study Group. Allocating funds to prevention of cardiovascular disease in light of the NCEP ATP III guidelines. *Am J Manag Care*. 2003;9(7):477-89.
12. Caro JJ, Ishak KJ, **Huybrechts KF**, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. *Osteoporos Int*. 2004;15(12):1003-8.
13. **Huybrechts KF**, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. *Kidney Int*. 2005;67:1532-8.
14. **Huybrechts KF**, Caro JJ, Wilson DA, O'Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. *Value Health*. 2005;8(5): 549-61.
15. **Huybrechts KF**, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. *Bone*. 2006;38(6):922-8.
16. Caro JJ, **Huybrechts KF**, Xenakis J, O'Brien JA, Rajagopalan K, Lee K. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: An economic analysis of clinical trials. *Curr Med Res Opin*. 2006;22(11):2233-42.
17. **Huybrechts KF**, Caro JJ, Xenakis JJ, Vemmos KN. The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry. *Cerebrovasc Dis*. 2008;26(4):381-7.
18. **Huybrechts KF**, Caro JJ, O'Brien JA. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. *Value Health*. 2009;12(1):16-9.
19. **Huybrechts KF**, Mikkelsen EM, Christensen T, Riis AH, Hatch EE, Wise LA, Sørensen HT, Rothman KJ. A successful implementation of e-epidemiology: the Danish pregnancy planning study 'Snart-Gravid'. *Eur J Epidemiol*. 2010;25(5):297-304.
20. Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, **Huybrechts KF**.

Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. *PLOS ONE*. 2011;6(4):e18210.

21. **Huybrechts KF**, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospitalization for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. *CMAJ*. 2011;183(7):E411-9.
22. Wise LA, Mikkelsen EM, Rothman KJ, Riis AH, Sørensen HT, **Huybrechts KF**, Hatch EE. A prospective cohort study of menstrual characteristics and time to pregnancy. *Am J Epidemiol*. 2011;174(6):701-9.
23. **Huybrechts KF**, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, Schneeweiss S. Comparison of different approaches to confounding adjustment in a study on the effect of antipsychotic medication on mortality in older nursing home patients. *Am J Epidemiol*. 2011;174(9):1089-99.
24. Myers JA, Rassen JA, Gagne JJ, **Huybrechts KF**, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. *Am J Epidemiol*. 2011;174(11):1213-22.
25. **Huybrechts KF**, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. *J Clin Psychopharm*. 2012;32(1):11-7.
26. **Huybrechts KF**, Schneeweiss S, Gerhard T, Olfson M, Avorn J, Levin R, Lucas JA, Crystal S. Comparative safety of antipsychotic medications in nursing home residents. *J Am Geriatr Soc*. 2012;60(3):420-9.
27. **Huybrechts KF**, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older nursing home residents prescribed specific antipsychotic medications: Population-based cohort study. *BMJ*. 2012;344:e977.
28. Zoëga H, Rothman K, **Huybrechts KF**, Ólafsson Ö, Baldursson G, Almarsdóttir A, Jónsdóttir S, Halldórsson M, Hernandez-Diaz S, Valdimarsdóttir, U. A population-based study of stimulant drug treatment for ADHD and academic progress in children. *Pediatrics*. 2012;130(1):e53-62.
29. Bateman BT, Hernandez-Diaz S, **Huybrechts KF**, Palmsten K, Mogun H, Ecker JL, Fischer MA. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. *Hypertension*. 2012;60(4):913-20.
30. **Huybrechts KF**, Seeger JD, Rothman KJ, Glynn RJ, Avorn J, Schneeweiss S. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: A legitimate concern or much ado about nothing? *Circ Cardiovasc Qual Outcomes*. 2012;5(5):e61-4.
31. **Huybrechts KF**, Palmsten K, Mogun H, Kowal M, Avorn J, Setoguchi-Iwata S, Hernandez-Diaz S. National trends in antidepressant medication treatment among publicly insured pregnant women. *Gen Hosp Psychiatry*. 2013;35(3):265-7.1.
32. Brunelli SM, Gagne JJ, **Huybrechts KF**, Wang SV, Patrick AR, Rothman KJ, Seeger JD. Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. *Pharmacoepidemiol Drug Saf*. 2013; 22(5):542-50.
33. Palmsten K, **Huybrechts KF**, Mogun H, Kowal MK, Williams PL, Michels KB, Setoguchi S, Hernández-Díaz S. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: Design considerations. *PLOS ONE*. 2013;8(6):e67405.
34. Bateman BT, **Huybrechts KF**, Hernandez-Diaz S, Liu J, Ecker JL, Avorn J. Methylergonovine maleate and the risk of myocardial ischemia and infarction. *Am J Obstet Gynecol*. 2013;209(5):459.e1-e13.
35. Palmsten K, **Huybrechts KF**, Michels KB, Williams PL, Mogun H, Setoguchi S, Hernández-Díaz S. Antidepressant use and risk for preeclampsia. *Epidemiology*. 2013;24(5):682-91.
36. Palmsten K, Hernández-Díaz S, **Huybrechts KF**, Williams PL, Michels KB, Achtyes ED, Mogun

- H, Setoguchi S. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. *BMJ*. 2013;347:f4877.
37. Bateman BT, Hernandez-Diaz S, **Huybrechts KF**, Palmsten K, Mogun H, Ecker JL, Seely EW, Fischer MA. Outpatient calcium-channel blockers and the risk of postpartum hemorrhage: A cohort study. *BJOG*. 2013;120(13):1668-76; discussion 1676-7.
 38. Bateman BT, Mhyre JM, Hernandez-Diaz S, **Huybrechts KF**, Fischer MA, Creanga AA, Callaghan WM, Gagne JJ. Development of a comorbidity index for use in obstetric patients. *Obstet Gynecol*. 2013;122(5):957-65.
 39. Gerhard T, **Huybrechts K**, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. *Br J Psychiatry*. 2014;205(1):44-51.
 40. Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, **Huybrechts KF**. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. *Anesthesiology*. 2014;120(5):1216-24.
 41. Desai RJ, Hernandez-Diaz S, Bateman BT, **Huybrechts KF**. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. *Obstet Gynecol*. 2014;123(5):997-1002.
 - Desai RJ, Hernandez-Diaz S, Bateman BT, **Huybrechts KF**. In Reply: Cho et al. *Obstet Gynecol*. 2014;124(3):638.
 42. **Huybrechts KF**, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: A systematic review and meta-analysis. *PLOS ONE*. 2014;26;9(3):e92778.
 43. **Huybrechts KF**, Gerhard T, Franklin JM, Levin R, Crystal S, Schneeweiss S. Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research. *Pharmacoepidemiol Drug Saf*. 2014;23(8):830-8.
 44. **Huybrechts KF**[†], Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernandez-Diaz S. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*. 2014;19;370(25):2397-407.
 - **Huybrechts KF**, Hernández-Díaz S, Avorn J. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*. 2014;371(12):1168-9.
 45. Palmsten K, **Huybrechts KF**, Kowal MK, Mogun H, Hernández-Díaz S. Validity of maternal and infant outcomes within nationwide Medicaid data. *Pharmacoepidemiol Drug Saf*. 2014;23(6):646-55.
 46. Bateman BT, Tsen LC, Liu J, Butwick AJ, **Huybrechts KF**. Patterns of second-line uterotonic use in a large sample of hospitalizations for childbirth in the United States: 2007-2011. *Anesth Analg*. 2014;119(6):1344-9.
 - Bateman BT, Butwick AJ, **Huybrechts KF**. Patterns of second-line uterotonic use in a large sample of hospitalizations for childbirth in the United States: 2007-2011--Reply. *Anesth Analg*. 2015;121(5):1397-8.
 47. Checchi KD, **Huybrechts KF**, Avorn J, Kesselheim AS. Electronic medication packaging devices and medication adherence: a systematic review. *JAMA*. 2014;312(12):1237-47. PMC4209732
 48. Bateman BT, **Huybrechts KF**, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. *Am J Obstet Gynecol*. 2015; 212(3):337.e1-14.
 49. Kesselheim AS, **Huybrechts KF**, Choudhry NK, Fulchino LA, Isaman DL, Kowal MK, Brennan TA. Prescription drug insurance coverage and patient health outcomes: a systematic review. *Am J Public Health*. 2015;105(2):e17-30.
 50. Park Y, Franklin JM, Schneeweiss S, Levin R, Crystal S, Gerhard T, **Huybrechts KF**. Antipsychotics and mortality: Adjusting for mortality risk scores to address confounding by terminal illness. *J Am Geriatr Soc*. 2015;63(3):516-23.

51. Bateman BT[†], Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, Desai RJ, Allen-Coleman C, Mogun H, Avorn J, **Huybrechts KF**. Statins and congenital malformations: cohort study. *BMJ*. 2015;350:h1035.
52. Franklin JM, Schneeweiss S, **Huybrechts KF**, Glynn RJ. Evaluating possible confounding by prescriber in comparative effectiveness research. *Epidemiology*. 2015;26(2):238-41.
53. Desai RJ, **Huybrechts KF**, Hernandez-Diaz S, Mogun H, Patorno E, Kaltenbach K, Kerzner LS, Bateman BT. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. *BMJ*. 2015;350:h2102.
54. **Huybrechts KF**, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, Levin R, Mogun H, Hernandez-Diaz S. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. *JAMA*. 2015;313(21):2142-51.
55. **Huybrechts KF**, Bateman BT, Hernandez-Diaz S. Maternal Antidepressant Use and Persistent Pulmonary Hypertension of the Newborn--Reply. *JAMA*. 2015;314(12):1294.
56. Swanson SA, Hernandez-Diaz S, Palmsten K, Mogun H, Olfson M, **Huybrechts KF**. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. *Pharmacoepidemiol Drug Saf*. 2015;24(9):934-42.
57. Bateman BT, **Huybrechts KF**, Maeda A, Desai R, Patorno E, Seely EW, Ecker JL, Allen-Coleman C, Mogun H, Hernandez-Diaz S, Fischer MA. Calcium channel blocker exposure in late pregnancy and the risk of neonatal seizures. *Obstet Gynecol*. 2015;126(2):271-8.
58. Palmsten K, Hernandez-Diaz S, Chambers CD, Mogun H, Lai S, Gilmer TP, **Huybrechts KF**. The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program. *Obstet Gynecol*. 2015;126(3):465-73.
59. Seeger JD, Bykov K, Bartels DB, **Huybrechts KF**, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. *Thromb Haemost*. 2015;114(6):1277-89.
60. Desai RJ, **Huybrechts KF**, Bateman BT, Hernandez-Diaz S, Mogun H, Gopalakrishnan C, Patorno E, Kim SC. Patterns and secular trends in use of immunomodulatory agents during pregnancy in women with rheumatologic conditions. *Arthritis Rheumatol*. 2016;68(5):1183-9.
61. Rough K, Bateman BT, Patorno E, Desai RJ, Park Y, Hernandez-Diaz S, **Huybrechts KF**. Suppression of substance abuse claims in Medicaid data and rates of diagnoses for non-substance abuse conditions. *JAMA* 2016;315(11):1164-6.
62. Ladha K, Patorno E, **Huybrechts KF**, Liu J, Rathmell JP, Bateman BT. Variations in the use of perioperative multimodal analgesic therapy. *Anesthesiology* 2016;124(4):837-45.
63. Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, Landon JE, Rathmell JP, **Huybrechts KF**, Fischer MA, Choudhry NK. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. *Am J Obstet Gynecol*. 2016;215(3):353.e1-e18.
64. Menendez ME, Lu N, **Huybrechts KF**, Ring D, Barnes CL, Ladha K, Bateman BT. Variation in use of blood transfusion in primary total hip and knee arthroplasties. *J Arthroplasty*. 2016; 31(12):2757-63.e2
65. **Huybrechts KF**[†], Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Cohen JM, Panchaud A, Cohen L, Bateman BT. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatry*. 2016;73(9):938-46.
 - Editorial: Wisner KL, Jeong H, Chambers C. Use of Antipsychotics During Pregnancy: Pregnant Women Get Sick-Sick Women Get Pregnant. *JAMA Psychiatry*. 2016;73(9):901-3.
66. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Maeda A, Fischer MA, Hernandez-Diaz S, **Huybrechts KF**. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and

- bradycardia. *Pediatrics*. 2016;138(3): e20160731.
67. Desai R[†], Rothman K, Bateman BT, Hernandez-Diaz S, **Huybrechts KF**. A propensity score based fine stratification approach for confounding adjustment when exposure is infrequent. *Epidemiology*. 2017;28(2):249-57.
 68. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Dejene SZ, Fischer MA, Friedman AM, Hernandez-Diaz S, **Huybrechts KF**. Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. *Obstet Gynecol*. 2017;129(1):174-84.
 69. **Huybrechts KF**, Desai RJ, Park M, Gagne JJ, Najafzadeh M, Avorn J. The potential return on public investment in detecting adverse drug effects. *Med Care*. 2017;55(6):545-51.
 70. Kim DH, **Huybrechts KF**, Patorno E, Marcantonio ER, Park Y, Levin R, Abdurrob A, Bateman BT. Adverse events associated with antipsychotic use in hospitalized older adults after cardiac surgery. *J Am Geriatr Soc*. 2017; 65(6):1229-37.
 71. Dong YH, Bykov K, Choudhry NK, Donneyong MM, **Huybrechts KF**, Levin R, Schneeweiss S, Gagne JJ. Clinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors: a multidatabase observational cohort study. *J Clin Psychopharmacol*. 2017;37(2):200-9.
 72. Desai RJ, Bateman BT, **Huybrechts KF**, Patorno E, Hernandez-Diaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. *BMJ*. 2017;356:j895.
 73. Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, **Huybrechts KF**, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D. International trends in clozapine use: a study in 17 countries. *Acta Psychiatr Scand*. 2017;136(1):37-51.
 74. Patorno E, Bateman BT, **Huybrechts KF**, MacDonald SC, Cohen JM, Desai RJ, Panchaud A, Mogun H, Pennell PB, Hernandez-Diaz S. Pregabalin use early in pregnancy and the risk of major congenital malformations. *Neurology*. 2017;88(21):2020-5.
 75. Kim DH, Lee J, Kim CA, **Huybrechts KF**, Bateman BT, Patorno E, Marcantonio ER. Evaluation of algorithms to identify delirium in administrative claims and drug utilization database. *Pharmacoepidemiol Drug Saf*. 2017;26(8):945-53.
 76. Rough K, Sun JW, Seage GR 3rd, Williams PL, **Huybrechts KF**, Bateman BT, Hernandez-Diaz S. Zidovudine use in pregnancy and congenital malformations. *AIDS*. 2017;31(12):1733-43.
 77. Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, **Huybrechts KF**, Clancy CR, Hopp SB, Ecker JL, Ende H, Grewe K, Raposo Corradini B, Schoenfeld RE, Sankar K, Day LJ, Harris L, Booth JL, Flood P, Bauer ME, Tsen LC, Landau R, Leffert LR. Patterns of opioid prescription and use after cesarean delivery. *Obstet Gynecol*. 2017;130(1):29-35.
 78. Park Y, **Huybrechts KF**, Cohen JM, Bateman BT, Desai RJ, Patorno E, Mogun H, Cohen LS, Hernandez-Diaz S. Antipsychotic medication use among publicly insured pregnant women in the United States. *Psychiatr Serv*. 2017;68(11):1112-19.
 79. Patorno E, **Huybrechts KF**, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. *N Engl J Med*. 2017;376(23):2245-54.
 - Patorno E, **Huybrechts KF**, Hernandez-Diaz S. Lithium Use in Pregnancy and the Risk of Cardiac Malformations - Reply. *N Engl J Med*. 2017;377(9):893-4.
 80. Patorno E, Glynn RJ, Levin R, Lee MP, **Huybrechts KF**. Benzodiazepines and risk of all cause mortality in adults: cohort study. *BMJ*. 2017;358:j2941.
 81. Hálfðánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, **Huybrechts KF**, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M,

- López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ. International trends in antipsychotic use: A study in 16 countries, 2005-2014. *Eur Neuropsychopharmacol.* 2017;27(10):1064-76.
82. **Huybrechts KF**[†], Bateman BT, Desai RJ, Hernandez-Diaz S, Rough K, Mogun H, Kerzner LS, Davis JM, Stover M, Bartels D, Cottral J, Patorno E. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. *BMJ.* 2017;358:j3326.
- Editorial: Patrick SW, Cooper WO, Davis MM. Prescribing opioids and psychotropic drugs in pregnancy. *BMJ.* 2017;358:j3616.
83. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, **Huybrechts KF**. Placental complications associated with psychostimulant use in pregnancy. *Obstet Gynecol.* 2017;130(6):1192-201.
84. Franklin JM, Dejene S, **Huybrechts KF**, Wang SV, Kulldorff M, Rothman KJ. A bias in the evaluation of bias comparing randomized trials with nonexperimental studies. *Epidemiol Methods.* 2017;6(1):20160018.
85. Ladha KS, Bateman BT, Houle TT, De Jong MAC, Vidal Melo MF, **Huybrechts KF**, Kurth T, Eikermann M. Variability in the use of protective mechanical ventilation during general anesthesia. *Anesth Analg.* 2018;126(2):503-12.
86. Mundkur ML, Rough K, **Huybrechts KF**, Levin R, Gagne JJ, Desai RJ, Patorno E, Choudhry NK, Bateman BT. Patterns of opioid initiation at first visits for pain in United States primary care settings. *Pharmacoepidemiol Drug Saf.* 2018;27(5):495-503
87. **Huybrechts KF**[†], Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernandez-Diaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: A cohort study from the International Pregnancy Safety Study Consortium. *JAMA Psychiatry.* 2018;75(2):167-75.
88. Hernandez-Diaz S, **Huybrechts KF**, Desai RJ, Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. *Neurology.* 2018;90(4):e342-51.
89. Bermas BL, Kim SC, **Huybrechts K**, Mogun H, Hernandez-Diaz S, Bateman BT, Desai RJ. Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. *Lupus.* 2018;27(6):1012-17.
90. Wang SV, **Huybrechts KF**, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. *Pharmacoepidemiol Drug Saf.* 2018;27(4):383-90.
91. Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, **Huybrechts KF**. Use of haloperidol vs. atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: a cohort study. *BMJ.* 2018; 360:k1218.
92. Ripollone J, **Huybrechts KF**, Rothman K, Ferguson R, Franklin JM. Implications of the propensity score matching paradox in pharmacoepidemiology. *Am J Epidemiol.* 2018; 187(9):1951-61.
93. Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, **Huybrechts KF**. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. *Am J Psychiatry.* 2018;175(6):564-74.
94. Panchaud A, Cohen JM, Patorno E, **Huybrechts K**, Desai RJ, Gray K, Mogun H, Hernandez-Diaz S, Bateman B. Anticonvulsants and the risk of perinatal bleeding complications: A pregnancy

- cohort study. *Neurology*. 2018;91(6):e533-42.
95. Mundkur ML, Franklin J, **Huybrechts KF**, Fischer MA, Kesselheim AS, Linder JA, Landon J, Patorno E. Changes in outpatient use of antibiotics by adults in the United States, 2006-2015. *Drug Saf*. 2018;41(12):1333-42.
 96. Prabhu M, Garry EM, Hernandez-Diaz S, MacDonald SC, **Huybrechts KF**, Bateman BT. Frequency of opioid dispensing after vaginal delivery. *Obstet Gynecol*. 2018;132(2):459-65.
 97. Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, Nguyen M, Gagne JJ, Patorno E, **Huybrechts KF**, Major JM, Zhou E, Reidy M, Cosgrove A, Schneeweiss S, Kulldorff M. Data mining for adverse drug events with a propensity score matched tree-based scan statistic. *Epidemiology*. 2018;29(6):895-903.
 98. Ladha KS, Gagne JJ, Patorno E, **Huybrechts KF**, Rathmell JP, Wang SV, Bateman BT. Opioid overdose after surgical discharge. *JAMA*. 2018;320(5):502-4.
 99. Kim DH, Mahesri M, Bateman BT, **Huybrechts KF**, Inouye SK, Marcantonio ER, Herzig SJ, Ely EW, Pisani MA, Levin R, Avorn J. Longitudinal trends and variation in antipsychotic use in older adults after cardiac surgery. *J Am Geriatr Soc*. 2018;66(8):1491-8.
 100. Freeman MP, Farchione T, Yao L, Sahin L, Taylor L, **Huybrechts KF**, Nonacs R, Sosinsky AZ, Viguera AC, Cohen LS. Psychiatric medications and reproductive safety: Scientific and clinical perspectives pertaining to the US FDA pregnancy and lactation labeling rule. *J Clin Psychiatry*. 2018;79(4):18ah38120.
 101. Bortoletto P, Prabhu M, Garry EM, **Huybrechts KF**, Anchan RM, Bateman BT. Opioid dispensing patterns after oocyte retrieval. *Fertil Steril*. 2018;110(5):905-9.
 102. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernandez-Diaz S, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Selmer R, **Huybrechts KF**, Zoega H. β -blocker use in pregnancy and the risk for congenital malformations: an international cohort study. *Ann Intern Med*. 2018;169(10):665-3.
 103. **Huybrechts KF**[†], Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, Desai RJ, Mogun H, Bateman BT. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. *JAMA*. 2018;320(23):2429-37.
 - Editorial: Haas DM. Helping pregnant women and clinicians understand the risk of ondansetron for nausea and vomiting during pregnancy. *JAMA*. 2018;320(23):2425-26.
 104. **Huybrechts KF**, Gopalakrishnan C, Franklin JM, Zint K, Franca LR, Bartels DB, Landon J, Schneeweiss S. Claims data studies of direct oral anticoagulants can achieve balance in important clinical parameters only observable in electronic health records. *Clin Pharmacol Ther*. 2019;105(4):979-93.
 105. Rough K, **Huybrechts KF**, Hernandez-Diaz S, Desai RJ, Patorno E, Bateman BT. Using prescription claims to detect aberrant behaviors with opioids: comparison and validation of 5 algorithms. *Pharmacoepidemiol Drug Saf*. 2019;28(1):62-69.
 106. Schneeweiss S, Gopalakrishnan C, Bartels DB, Franklin JM, Zint K, Kulldorff M, **Huybrechts KF**. Sequential monitoring of the comparative effectiveness and safety of dabigatran in routine care. *Circ Cardiovasc Qual Outcomes*. 2019;12(2):e005173.
 107. Sultana J, Hurtado I, Bejarano-Quisoboni D, Giorgianni F, **Huybrechts KF**, Lu Z, Patorno E, Sanfèlix-Gimeno G, Tari DU, Trifirò G. Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. *Eur J Clin Pharmacol*. 2019;75(7):1005-15.
 108. Gopalakrishnan C, Schneeweiss S, Bartels DB, Zint K, Santiago Ortiz A, **Huybrechts KF**. Evaluating utilization patterns of oral anticoagulants in routine care. *J Thromb Haemost*. 2019;17(7):1033-43.
 109. **Huybrechts KF**, Bateman BT, Hernández-Díaz S. Use of real-world evidence from healthcare

- utilization data to evaluate drug safety during pregnancy. *Pharmacoepidemiol Drug Saf.* 2019;28(7):906-22.
110. Cohen JM, **Huybrechts KF**, Patorno E, Desai RJ, Mogun H, Bateman BT, Hernández-Díaz S. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. *J Clin Psychiatry.* 2019;80(4):18m12572.
 111. Straub L, **Huybrechts KF**, Bateman BT, Mogun H, Gray KJ, Holmes LB, Hernandez-Diaz S. The impact of technology on the diagnosis of congenital malformations. *Am J Epidemiol.* 2019;188(11):1892-901.
 112. Cohen JM, Bateman BT, **Huybrechts KF**, Mogun H, Yland J, Schatz M, Wurst KE, Hernandez-Diaz S. Poorly controlled asthma during pregnancy remains common in the United States. *J Allergy Clin Immunol Pract.* 2019;7(8):2672-80.e10.
 113. Dave CV, Patorno E, Franklin JM, **Huybrechts K**, Sarpatwari A, Kesselheim AS, Bateman BT. Impact of state laws restricting opioid duration on characteristics of new opioid prescriptions. *J Gen Intern Med.* 2019;34(11):2339-2341.
 114. MacDonald SC, Cohen JM, Panchaud A, McElrath TF, **Huybrechts KF**, Hernández-Díaz S. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. *Pharmacoepidemiol Drug Saf.* 2019;28(9):1211-21.
 115. Pottgård A, Klungel O, Winterstein A, **Huybrechts K**, Hallas J, Schneeweiss S, Evans S, Bate A, Pont L, Trifirò G, Smith M, Bourke A. The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. *Pharmacoepidemiol Drug Saf.* 2019;28(12):1640-1.
 116. Cesta CE, Cohen JM, Pazzagli L, Bateman BT, Bröms G, Einarsdóttir K, Furu K, Havard A, Heino A, Hernandez-Diaz S, **Huybrechts KF**, Karlstad Ø, Kieler H, Li J, Leinonen MK, Gulseth HL, Tran D, Yu Y, Zoega H, Odsbu I. Antidiabetic medication use during pregnancy: an international utilization study. *BMJ Open Diabetes Res Care.* 2019;7(1):e000759.
 117. Labuda SM, Huo Y, Kacanek D, Patel K, **Huybrechts K**, Jao J, Smith C, Hernandez-Diaz S, Scott G, Burchett S, Kakkar F, Chadwick EG, Van Dyke RB; Pediatric HIV/AIDS Cohort Study. Rates of Hospitalization and Infection-Related Hospitalization Among HIV-Exposed Uninfected Children Compared to HIV-Unexposed Uninfected Children in the United States, 2007-2016. *Clin Infect Dis.* 2020;71(2):332-9.
 118. **Huybrechts KF**, Hernandez-Diaz S, Straub L, Gray KJ, Zhu Y, Mogun H, Bateman BT. Intravenous ondansetron in pregnancy and risk of congenital malformations. *JAMA.* 2020;323(4):372-4.
 119. Ripollone JE, **Huybrechts KF**, Rothman KJ, Ferguson RE, Franklin JM. Evaluating the utility of coarsened exact matching for pharmacoepidemiology using real and simulated claims data. *Am J Epidemiol.* 2020;189(6):613-22.
 120. Hernández-Díaz S, Bateman BT, Palmsten K, Schneeweiss S, **Huybrechts KF**. Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. *Pharmacoepidemiol Drug Saf.* 2020;29(9):1151-8.
 121. **Huybrechts KF**, Gopalakrishnan C, Bartels DB, Zint K, Gurusamy VK, Landon J, Schneeweiss S. Safety and effectiveness of dabigatran and other direct oral anticoagulants compared to warfarin in patients with atrial fibrillation. *Clin Pharmacol Ther.* 2020;107(6):1405-19.
 122. **Huybrechts KF**, Bateman BT, Pawar A, Bessette LG, Mogun H, Levin R, Li H, Motsko S, Scantamburlo Fernandes MF, Upadhyaya HP, Hernandez-Diaz S. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. *BMJ.* 2020;368:m237.
 123. Fralick M, Colacci M, Schneeweiss S, **Huybrechts KF**, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. *Ann Intern Med.* 2020;172:463-73.

124. Yland J, Bateman BT, **Huybrechts KF**, Brill G, Schatz M, Wurst KE, Hernandez-Diaz S. Perinatal outcomes associated with maternal asthma and its severity and control during pregnancy. *J Allergy Clin Immunol Pract.* 2020;8(6):1928-37.e3.
125. He M, **Huybrechts KF**, Dejene SZ, Straub L, Bartels D, Burns S, Combs DJ, Cottral J, Gray KJ, Manning-Geist BL, Mogun H, Reimers RM, Hernandez-Diaz S, Bateman BT. Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract database. *Pharmacoepidemiol Drug Saf.* 2020;29(4):419-26.
126. Zhu Y, Bateman BT, Gray K, Hernandez-Diaz S, Mogun H, Straub L, **Huybrechts KF**. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. *BMJ.* 2020;369:m1494.
127. Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarsdóttir K, Engeland A, Furu K, Gissler M, Havard A, Hernandez-Diaz S, **Huybrechts KF**, Karlstad Ø, Leinonen MK, Li J, Man KK, Pazzagli L, Schaffer A, Schink T, Wang Z, Yu Y, Zoega H, Bröms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. *Schizophr Res.* 2020;220:106-15.
128. Wesselink AK, Bresnick KA, Hatch EE, Rothman KJ, Mikkelsen EM, Wang TR, **Huybrechts KF**, Wise LA. Association between male use of pain medication and fecundability. *Am J Epidemiol.* 2020;189(11):1348-59.
129. Reale SC, Fields KG, Lumbreras-Marquez MI, King CH, Burns SL, **Huybrechts KF**, Bateman BT. Association between number of in-person health care visits and SARS-CoV-2 infection in obstetrical patients. *JAMA.* 2020;324(12):1210-12.
130. Chen ST, **Huybrechts KF**, Bateman BT, Hernández-Díaz S. Trends in human papillomavirus vaccination in commercially insured children in the United States. *Pediatrics.* 2020;146(4):e20193557.
131. Messinger CJ, Lipsitch M, Bateman BT, He M, **Huybrechts KF**, MacDonald S, Mogun H, Mott K, Hernández-Díaz S. Association between congenital cytomegalovirus and the prevalence at birth of microcephaly in the United States. *JAMA Pediatr.* 2020;174(12):1159-67.
132. Sun JW, Franklin JM, Rough K, Desai RJ, SHernández-Díaz S, **Huybrechts KF**, Bateman BT. Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data. *PLOS ONE.* 2020;15(10):e0241083.
133. Yland JJ, Bresnick KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, Sørensen HT, **Huybrechts KF**, Wise LA. Pregravid contraceptive use and fecundability: prospective cohort study. *BMJ.* 2020; 371:m3966.
134. Ripollone JE, **Huybrechts KF**, Rothman KJ, Ferguson RE, Franklin JM. Brief discussion on sampling variability in 1:1 propensity score matching without replacement. *Pharmacoepidemiol Drug Saf.* 2020;29(9):1194-1197.
135. **Huybrechts KF**, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, Desai R, Hernandez-Diaz S. Hydroxychloroquine early in pregnancy and risk of birth defects. *Am J Obstet Gynecol.* 2021;224(3):290.e1-e22.
136. Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, **Huybrechts KF**. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. *JAMA Psychiatry.* 2021;78(1):91-100.
137. Sun JW[†], Bourgeois FT, Haneuse S, Hernández-Díaz S, Landon JE, Bateman BT, **Huybrechts KF**. Development and validation of a pediatric comorbidity index. *Am J Epidemiol.* 2021;190(5):918-27.
138. Bröms G, Friedman S, Kim SC, Wood ME, Hernandez-Diaz S, Brill G, Bateman BT, **Huybrechts KF**, Desai RJ. The patterns of use of medications for inflammatory bowel disease during pregnancy in the US and Sweden are changing. *Inflamm Bowel Dis.* 2021;27(9):1427-34.
139. **Huybrechts KF**[†], Kulldorff M, Hernandez-Diaz S, Bateman BT, Zhu Y, Mogun H, Wang SV.

- Active surveillance of the safety of medications used in pregnancy. *Am J Epidemiol*. 2021;190(6):1159-68.
140. Sun JW, Hernández-Díaz S, Bourgeois FT, Haneuse S, Brill G, Bateman BT, **Huybrechts KF**. Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019. *Diabetes Obes Metab*. 2021;23(2):444-54.
 141. Szmulewicz A, Bateman BT, Levin R, **Huybrechts KF**. The risk of overdoses with concomitant use of Z-drugs and prescription opioids: a population-based cohort study. *Am J Psychiatry*. 2021;178(7):643-50.
 142. Bateman BT, **Huybrechts KF**. Drug-drug interactions in pregnancy: An important frontier for pharmacoepidemiology. *Paediatr Perinat Epidemiol*. 2021;35(2):194-95.
 143. Zhu Y, **Huybrechts KF**, Desai RJ, Franklin JM, Hernandez-Diaz S, Krumme A, Straub L, Neuman M, Wunsch H, Levin R, Mogun H, Bateman BT. Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. *Am J Obstet Gynecol MFM*. 2021;3(2):100304.
 144. Straub L, **Huybrechts KF**, Hernandez-Diaz S, Zhu Y, Vine S, Desai RJ, Gray KJ, Bateman BT. Chronic prescription opioid use in pregnancy in the United States. *Pharmacoepidemiol Drug Saf*. 2021;30(4):504-13.
 145. **Huybrechts KF**, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, Desai RJ, Hernandez-Diaz S. Hydroxychloroquine early in pregnancy and risk of birth defects. *Am J Obstet Gynecol*. 2021;224(3):290.e1-e22.
 - **Huybrechts KF**, Bateman BT, Hernandez-Diaz S. Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. *Am J Obstet Gynecol*. 2021;224(5):549-50.
 146. Reale SC, Lumbreras-Marquez MI, King CH, Burns SL, Fields KG, Diouf K, Goldfarb IT, Ciaranello AL, Robinson JN, Gregory KE, **Huybrechts KF**, Bateman BT. Patient characteristics associated with SARS-CoV-2 infection in parturients admitted for labour and delivery in Massachusetts during the spring 2020 surge: A prospective cohort study. *Paediatr Perinat Epidemiol*. 2021;35(1):24-33.
 147. Bateman BT, Hernandez-Diaz S, Straub L, Zhu Y, Gray KJ, Desai RJ, Mogun H, Gautam N, **Huybrechts KF**. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. *BMJ*. 2021;372:n102.
 148. Hernandez-Diaz S, Bateman BT, Straub L, Zhu Y, Mogun H, Fischer M, **Huybrechts KF**. Safety of tenofovir disoproxil fumarate for pregnant women facing the coronavirus disease 2019 pandemic. *Am J Epidemiol*. 2021;190(11):2339-49.
 149. Mott K, **Huybrechts KF**, Glynn RJ, Mogun H, Hernández-Díaz S. Tetanus, diphtheria, acellular pertussis vaccination during pregnancy and risk of pertussis in the newborn in publicly and privately insured mother-infant pairs in the United States. *Pediatr Infect Dis J*. 2021;40(7):681-7.
 150. Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, LaCivita C, Manzo C, Zhou EH, Pinnow E, Dal Pan GJ, Gagne JJ, **Huybrechts KF**, Feldman WB, Chin K, Kesselheim AS. A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs. *Drug Saf*. 2021;44(7):743-51.
 151. Wood ME, Chen ST, **Huybrechts KF**, Bateman BT, Gray KJ, Seely EW, Zhu Y, Mogun H, Paterno E, Hernández-Díaz S. Validation of a claims-based algorithm to identify pregestational diabetes among pregnant women in the United States. *Epidemiology*. 2021;32(6):855-9.
 152. Straub L, Bateman BT, Hernandez-Diaz S, York C, Zhu Y, Suarez EA, Lester B, Gonzalez L, Hanson R, Hildebrandt C, Homsy J, Kang D, Lee KWK, Lee Z, Li L, Longacre M, Shah N, Tukan N, Wallace F, Williams C, Zerriny S, Mogun H, **Huybrechts KF**. Validity of claims-based algorithms to identify neurodevelopmental disorders in children. *Pharmacoepidemiol Drug Saf*. 2021;30(12):1635-42.

153. Straub L, **Huybrechts KF**, Mogun H, Bateman BT. Association of neuraxial labor analgesia for vaginal childbirth with risk of autism spectrum disorder. *JAMA Netw Open*. 2021;4(12):e2140458.
154. Esposito DB, Bateman B, Werler M, Straub L, Mogun H, Hernandez-Diaz S, **Huybrechts K**. Ischemic placental disease, preterm delivery, and their association with opioid use during pregnancy. *Am J Epidemiol*. 2022;191(5):759-68.
 - Esposito DB, Bateman B, Werler M, Straub L, Mogun H, Hernandez-Diaz S, **Huybrechts K**. Esposito et al. respond to “Opioid use and ischemic placental disease.” *Am J Epidemiol*. 2022;191(5):773-4.
155. Straub L, **Huybrechts KF**, Hernández-Díaz S, Zhu Y, Vine S, Desai RJ, Gray KJ, Bateman BT. Trajectories of prescription opioid utilization during pregnancy among prepregnancy chronic users and risk of neonatal opioid withdrawal syndrome. *Am J Epidemiol*. 2022;191(1):208-19.
156. Shiner B, Forehand JA, Rozema L, Kulldorff M, Watts BV, Trefethen M, Jiang T, **Huybrechts KF**, Schnurr PP, Vincenti M, Gui J, Gradus JL. Mining clinical data for novel posttraumatic stress disorder medications. *Biol Psychiatry*. 2022;91(7):647-57.
157. Wood ME, Patorno E, **Huybrechts KF**, Bateman BT, Gray KJ, Seely EW, Vine S, Hernández-Díaz S. The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States. *Endocrinol Diabetes Metab*. 2022;5(2):e00319.
158. Straub L, Bateman BT, Hernandez-Diaz S, York C, Lester B, Wisner KL, McDougale CJ, Pennell PB, Gray KJ, Zhu Y, Suarez EA, Mogun H, **Huybrechts KF**. Neurodevelopmental disorders among publicly or privately insured children in the United States. *JAMA Psychiatry*. 2022;79(3):232-42.
159. Szmulewicz AG, Bateman BT, Levin R, **Huybrechts KF**. Risk of overdose associated with co-prescription of antipsychotics and opioids: a population-based cohort study. *Schizophr Bull*. 2022;48(2):405-13.
160. Straub L[†], Hernandez-Diaz S, Bateman BT, Wisner KL, Gray KJ, Pennell PB, Lester B, McDougale CJ, Suarez EA, Zhu Y, Zakoul H, Mogun H, **Huybrechts KF**. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. *JAMA Intern Med*. 2022;182(5):522-33.
 - Straub L, Hernández-Díaz S, **Huybrechts KF**. Do Not Panic About Prenatal Exposure to Antipsychotics Except for Aripiprazole?-Reply. *JAMA Intern Med*. 2022;182(10):1106-1107..
161. Shiner B, **Huybrechts KF**, Gui J, Rozema L, Forehand J, Watts BV, Jiang T, Hoyt JE, Esteves J, Schnurr PP, Ray K, Gradus JL. Comparative effectiveness of direct-acting antivirals for posttraumatic stress disorder in Veterans Affairs Patients with hepatitis C virus infection. *Am J Epidemiol*. 2022;191(9):1614-25.
162. Esposito DB, **Huybrechts KF**, Werler M, Straub L, Hernández-Díaz S, Mogun H, Bateman BT. Prescription opioid analgesic medication type and the risk of neonatal opioid withdrawal syndrome. *JAMA Netw Open*. 2022;5(8):e2228588.
163. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, Wisner KL, Gray KJ, Pennell PB, Lester B, McDougale CJ, Zhu Y, Mogun H, **Huybrechts KF**. Antidepressant Use During Pregnancy and the Risk of Neurodevelopmental Disorders in Children. *JAMA Intern Med*. 2022; 182(11):1149-60.
164. Suarez EA, **Huybrechts KF**, Straub L, Hernandez-Diaz S, Jones HE, Connery HS, Davis JM, Gray KJ, Lester B, Terplan M, Mogun H, Bateman BT. Neonatal and Maternal Adverse Outcomes Following Use of Buprenorphine Compared to Methadone for Treatment of Opioid Use Disorder in Pregnancy. *N Engl J Med*. 2022;387(22):2033-2044.
165. Kim S, Hernandez-Diaz S, Zhu Y, Wyszynski D, **Huybrechts KF**. Association between SARS-CoV-2 Infection during Pregnancy and Postpartum Depressive and Anxiety Symptoms: Finding from the International Registry of Coronavirus Exposure in Pregnancy (IRCEP) Study. *Arch Womens Ment Health* 2022;25(6):1105-1118.

166. Zhu Y, Bateman BT, Hernandez-Diaz S, Gray KJ, Straub L, Reimers RM, Manning-Geist B, Yoselevsky E, Taylor LG, Ouellet-Hellstrom R, Ma Y, Qiang Y, Hua W, **Huybrechts KF**. Validation of Claims-based Algorithms to Identify Non-Live Birth Outcomes. *Pharmacoepidemiol Drug Saf.* 2022 Nov 24. doi: 10.1002/pds.5574. Online ahead of print.
167. **Huybrechts KF**, Straub L, Karlsson P, Pazzagli L, Furu K, Gissler M, Hernandez-Diaz S, Norgaard M, Zoega H, Bateman BT, Cesta CE, Cohen JM, Leinonen MK, Reutfors J, Selmer RM, Suarez EA, Ulrichsen SP, Kieler H. Association of In-Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations: An International Study. *JAMA Psychiatry* 2023; 80(2):156-166.
168. Thai TN, Rasmussen SA, Smolinski NE, Nduaguba S, Zhu Y, Bateman BT, **Huybrechts KF**, Hernandez-Diaz S, Winterstein AG. Impact of continuous maternal enrollment on stillbirth gestational age distributions and maternal characteristics among Medicaid enrollees. *Am J Epidemiol.* 2023; 192(3):497-502.
169. Margulis AV, **Huybrechts K**. Identification of pregnancies in healthcare data: A changing landscape. *Pharmacoepidemiol Drug Saf.* 2023 Jan;32(1):84-86.
170. Zhu Y, Thai TN, Hernandez-Diaz S, Bateman BT, Winterstein AG, Straub S, Franklin JM, Gray KJ, Wyss R, Mogun H, Vine V, Taylor LG, Ouellet-Hellstrom R, Ma Y, Qiang Y, Hua W, **Huybrechts KF**. Development and validation of algorithms to estimate live birth gestational age in Medicaid Analytic eXtract data. *Epidemiology.* 2023;34(1):69-79.
171. Hernández-Díaz S, **Huybrechts KF**, Chiu YH, Yland JJ, Bateman BT, Hernán MA. Emulating a Target Trial of Interventions Initiated During Pregnancy with Healthcare Databases: The Example of COVID-19 Vaccination. *Epidemiology.* 2023;34(2):238-246.
- Hernández-Díaz S, **Huybrechts KF**, Hernán MA. Letter in response to Latour CD et al. *Epidemiology* 2024 (in press).
172. Bröms G, Hernandez-Diaz S, **Huybrechts KF**, Bateman BT, Kristiansen EB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Karlsson P, Klungsoyr K, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Kieler H. Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study. *J Clin Psychiatry.* 2023 Jan 16;84(1):22m14430.
173. Suarez EA, **Huybrechts KF**, Straub L, Hernandez-Diaz S, Creanga AA, Connery HS, Gray KJ, Vine SM, Jones HE, Bateman BT. Postpartum Opioid-Related Mortality in Publicly Insured Patients. *Obstet Gynecol* 2023;141(4):657-665.
- Editorial: Smid MC. Preventing Postpartum Opioid Overdoses. *Our Patients, Our Job. Patients.* *Obstet Gynecol* 2023 Mar 9. DOI: 10.1097/AOG.0000000000005140. Online ahead of print.
 - Featured on the *Obstetrics & Gynecology* Podcast as an Editors' Pick for April 2023
174. Savage TJ, Kronman MP, Sreedhara SK, Russo M, Lee SB, Oduol T, **Huybrechts KF**. Trends in the Antibiotic Treatment of Acute Sinusitis: 2003-2020. *Pediatrics* 2023;151(4):e2022060685.
175. Savage TJ, Wardell H, **Huybrechts KF**. Accuracy of identifying pediatric acute bacterial sinusitis diagnoses in outpatient claims data. *Pharmacoepidemiol Drug Saf.* 2023; 32(8):918-923.
176. Straub L, Bateman BT, Vine S, **Huybrechts KF**. Prevalence of Mental Health Diagnoses in Commercially Insured Children and Adolescents in the US Before and During the COVID-19 Pandemic. *JAMA Network Open* 2023; 6(5):e2314415.
177. Yland J, Wesselink AK, Regan AK, Hatch EE, Rothman KJ, Savitz DA, Wang TR, **Huybrechts KF**, Hernández-Díaz S, Eisenberg ML; Wise LA. A prospective cohort study of preconception COVID-19 vaccination and miscarriage. *Human Reproduction* 2023;38(12):2362-2372.
178. Cesta C, Hernández-Díaz S, **Huybrechts KF**, Bateman BT, Vine S, Seely EW, Patorno E. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data. *Pharmacoepidemiol Drug Saf.* 2023;32(12):1350-1359.

179. Savage TJ, Kronman MP, Kattinakere Sreedhara S, Lee SB, Oduol T, **Huybrechts KF**. Treatment Failure and Adverse Events after Amoxicillin-Clavulanate vs. Amoxicillin for Pediatric Acute Sinusitis. *JAMA* 2023; 330(11):1064-1073.
- Savage TJ, Kronman MP, **Huybrechts KF**. Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis-Reply. *JAMA*. 2024 Jan 16;331(3):258-259.
180. Hwang CS, Kesselheim AS, Sarpatwari A, **Huybrechts KF**, Brill G, Rome BN. Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018-2022: An Interrupted Time-Series Analysis. *Annals of Internal Medicine* 2023;176(11):1508-1515.
181. Cesta C, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, **Huybrechts KF**, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 analogues and other 2nd-line antidiabetics in early pregnancy: an international cohort study. *JAMA Internal Medicine* 2023 Dec 11:e236663.
182. Mansour O, Russo RG, Straub L, Bateman BT, Gray KJ, **Huybrechts KF**, Hernandez-Diaz S. Prescription Medication Use During Pregnancy in the United States 2011-2020: Trends and Safety Evidence. *AJOG* 2023 Dec 19:S0002-9378(23)02172-5.
183. Cohen JM, Alvestad S, Suarez EA, Schaffer A, Selmer RM, Havard A, Bateman BT, Cesta CE, Zoega H, Odsbu I, **Huybrechts KF**, Kjerpeseth LJ, Straub L, Leinonen MK, Bjørk M-H, Nørgaard M, Gissler M, Ulrichsen SP, Hernandez-Diaz S, Tomson T, Furu K. Comparative risk of major congenital malformations with antiseizure medication combinations versus valproate monotherapy in pregnancy. *Neurology* 2024;102(2):e207996.
184. Shupler M, **Huybrechts KF**, Leung M, Wei Y, Schwartz J, Li L, Koutrakis P, Hernández-Díaz S, Papatheodorou S. Short-term increases in NO₂ and O₃ concentrations during pregnancy and stillbirth risk in the US: A time-stratified, case-crossover study. *Environ Sci Technol* 2024; 58(2):1097-1108.
185. Suarez EA, Bateman BT, Straub L, Hernandez-Diaz S, Jones HE, Gray KJ, Connery HS, Davis JM, Lester B, Terplan M, Zhu Y, Vine SM, Mogun H, **Huybrechts KF**. First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations. *JAMA Internal Medicine* 2024 Jan 22:e236986. doi: 10.1001/jamainternmed.2023.6986. Epub ahead of print. PMID: 38252426; PMCID: PMC10804281.
- Editorial: Poland C, Stoltman JJK, Felton JW. Medication for the Treatment of Opioid Use Disorder in Pregnancy Is Essential. *JAMA Intern Med*. Published online January 22, 2024. Doi:10.1001/jamainternmed.2023.6977
 - Editorial: Nguemini Tiako MJ, Knight KR, Schiff DM. Prenatal Opioid Use Disorder Treatment-the Importance of Shared Decision-Making. *JAMA Intern Med*. 2024 Jan 22. doi: 10.1001/jamainternmed.2023.6976. Epub ahead of print. PMID: 38252420.
186. Chiu Y-H, **Huybrechts KF**, Zhu Y, Straub L, Bateman BT, Logan R, Hernández-Díaz S. Internal validation of gestational age estimation algorithms in healthcare databases using pregnancies conceived with fertility procedures. *Am J Epidemiol* 2024 (in press).
187. Shupler M, **Huybrechts KF**, Leung M, Wei Y, Schwartz J, Li L, Koutrakis P, Hernandez-Diaz S, Papatheodorou S. The association of short term increases in ambient PM_{2.5} and temperature exposures with stillbirth: racial/ethnic disparities among Medicaid recipients. *Am J Epidemiol* 2024 May 20:kwae083. doi: 10.1093/aje/kwae083. Online ahead of print. PMID: 38770979.
188. Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, **Huybrechts KF**. Prescription stimulant use during pregnancy and the risk of neurodevelopmental disorders in children. *JAMA Psychiatry* 2024 Jan 24:e235073. doi: 10.1001/jamapsychiatry.2023.5073. Epub ahead of print. PMID: 38265792; PMCID: PMC10809143.
189. Rotem RS, Weisskopf MG, **Huybrechts KF**, Hernandez-Diaz S. Paternal use of metformin during

- the sperm development period preceding conception and risk of major congenital malformations in newborns. *Annals of Internal Medicine* 2024;177(7):851-861.
190. Chiu Y-H, **Huybrechts KF**, Zhu Y, Straub L, Bateman BT, Logan, Hernández-Díaz S. Internal validation of gestational age estimation algorithms in healthcare databases using pregnancies conceived with fertility procedures. *Am J Epidemiol* 2024;193(8):1168-1175.
 191. Zhu Y, Hernandez-Diaz S, Bateman BT, Gray KJ, Alt EM, Straub L, Taylor LG, Ouellet-Hellstrom R, Ma Y, Qiang Y, Vine S, Mogun H, Hua W, **Huybrechts KF**. Development and validation of claims-based algorithms for estimating gestational age of spontaneous abortion and termination. *Am J Epidemiol* 2024 (in press).
 192. Hernandez-Diaz S, Straub L, Bateman BT, Zhu Y, Mogun H, Wisner KL, Gray KJ, Lester B, McDougle CJ, DiCesare E, Pennell PB, **Huybrechts KF**. Risk of Autism after Prenatal Topiramate, Valproate or Lamotrigine Exposure. *N Engl J Med* 2024;390:1069-1079.
 - Editorial: Meador KJ, [Risks of Fetal Exposure to Topiramate](#). *N Engl J Med* 2024;390:1141-1142
 193. Straub L, Wang SV, Hernandez-Diaz S, Gray KJ, Vine SM, Russo M, Mittal L, Bateman BT, Zhu Y, **Huybrechts KF**. Hierarchical Clustering Analysis to Inform Classification of Congenital Malformations for Surveillance of Medication Safety in Pregnancy. *Am J Epidemiol* 2024 Aug 9:kwae272. doi: 10.1093/aje/kwae272. Online ahead of print. PMID: 39123096.
 194. Leonard SA, Siadat S, Main EK, **Huybrechts KF**, El-Sayed YY, Hlatky MA, Atkinson J, Sujana A, Bateman BT. Prevalence and treatment of chronic hypertension during pregnancy in the United States, 2008-2021. *Hypertension* 2024; 81(8):1716-1723.
 195. Adomi M, McElrath TF, Hernandez-Diaz S, Vine SM, **Huybrechts KF**. TNF- α inhibitor use during pregnancy and the risk of preeclampsia: population-based cohort study. *Journal of Hypertension* 2024;42(9):1529-1537.
 196. Feldman WB, Mahesri M, Sarpatwari A, **Huybrechts KF**, Zhu Y, Hwang CS, Lii J, Lee SB, Kattinakere Sreedhara S, Toyserkani GA, Zhou EH, Zendel L, LaCivita C, Manzo C, Dal Pan GJ, Kesselheim AS, Bykov K. Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement on Ambrisentan: A Time-Series Analysis. *JAMA Network Open* 2024 (in press)
 197. Mahesri M, Sarpatwari A, **Huybrechts KF**, Lii J, Lee SB, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Kesselheim AS, Bykov K. Trends in Use and Claims for Risk Evaluation and Mitigation Strategy Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the US, 2000-2020. *Drug Saf.* 2024;47(9):909-919.
 198. Chiu Y-H, **Huybrechts KF**, Patorno E, Yland JJ, Cesta CE, Bateman BT, Seely EW, Hernán MA, Hernández-Díaz S. Metformin use in the first trimester of pregnancy and risk of non-live birth and congenital malformations: emulating a target trial using real-world data. *Annals of Internal Medicine* 2024;177(7):862-870.
 199. McEwen I, **Huybrechts KF**, Straub L, Hernández-Díaz S. Patterns of Paternal Medication Dispensation Around the Time of Conception. *Paediatric and Perinatal Epidemiology* 2024 Jul 1. doi: 10.1111/ppe.13098. Online ahead of print. PMID: 38949455.
 200. Straub L, Bateman BT, Hernández-Díaz S, Zhu Y, Suarez EA, Vine SM, Jones HE, Connery HS, Davis JM, Gray KJ, Lester B, Terplan M, Zakoul H, Mogun H, **Huybrechts KF**. Comparative Safety of In Utero Exposure to Buprenorphine Combined with Naloxone Versus Buprenorphine Alone. *JAMA* 2024 Aug 12:e2411501. doi: 10.1001/jama.2024.11501. Online ahead of print.
 201. Anike O, Zhang Q, Bhasin S, Flanders WD, Getahun D, Haw JS, **Huybrechts KF**, Lash TL, McCracken CE, Roblin D, Silverberg MJ, Suglia SF, Tangpricha V, Vupputuri S, Goodman M. Association between gender-affirming hormone therapy and measures of glucose metabolism: A longitudinal study. *J Clin Endocrinol Metab.* 2024 May 30:dgae353. doi: 10.1210/clinem/dgae353.

- Online ahead of print.PMID: 38815002.
202. Basham CA, Edrees H, **Huybrechts KF**, Hwang CS, Bateman BT, Bykov K. Tramadol use in US adults with commercial health insurance, 2005-2021. *American J Prev Med.* 2024 Jun 12:S0749-3797(24)00199-5. doi: 10.1016/j.amepre.2024.06.009. Online ahead of print.
 203. Yland JJ, **Huybrechts KF**, Wesselink AK, Straub L, Chiu Y-H, Seely EW, Paterno E, Bateman BT, Mogun H, Wise LA, Hernández-Díaz S. Perinatal outcomes associated with metformin use during pregnancy among women with pregestational type 2 diabetes mellitus. *Diabetes Care* 2024 Jul 23:dc232056. doi: 10.2337/dc23-2056. Online ahead of print.PMID: 39042587.
 204. Bea S, **Huybrechts KF**, Edrees HH, Basham CA, Vine SM, Glynn RJ, Bateman BT, Bykov K. Opioid overdose in patients with concomitant use of tramadol and clopidogrel versus alternative antiplatelet agents. *J Am Coll Cardiol.* 2024 (In press)

Research investigations published in Dutch

1. **Huybrechts K.** Cost-effectiveness analysis of the prophylactic use of antibiotics for total hip replacement (in Dutch). *Tijdschrift voor Sociale Gezondheidszorg* 1993;71:273-8.

Other peer-reviewed publications

1. **Huybrechts KF**, Caro JJ. The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature. *Curr Med Res Opin.* 2007;23(7):1627-36.
2. Caro JJ, **Huybrechts KF**. Case-control studies in pharmaco-economic research: an overview. *Pharmacoeconomics.* 2009;27(8):627-34.
3. Schneeweiss S, **Huybrechts KF**, Gagne JJ. Interpreting the quality of healthcare database studies on the comparative effectiveness of oral anticoagulants in routine care. *J Comp Eff Res.* 2013;3:33-41.
4. **Huybrechts KF**, Hernandez-Diaz S, Bateman B. Contextualizing potential risks of medications in pregnancy for the newborn: the case of ondansetron. *JAMA Pediatr.* 2020;174(8):747-8.
 - **Huybrechts KF**, Hernandez-Diaz S, Bateman BT. Antiemetic drugs during pregnancy: what can we learn from spontaneous reporting system database analyses?-Reply. *JAMA Pediatr.* 2021;175(3):327-8.
5. Wisner KL, Oberlander TF, **Huybrechts KF**. The association between antidepressant exposure and birth defects-are we there yet? *JAMA Psychiatry.* 2020;77(12):1215-16.
6. **Huybrechts KF**, Olfson M. Evaluating the liability of antidepressants to induce mania in depressed children and adolescents. *JAMA Psychiatry* 2023. Published online September 27, 2023. doi:10.1001/jamapsychiatry.2023.3525

Scholarship without named authorship

1. Wang SV, Sreedhara SK, Schneeweiss S; **REPEAT Initiative***. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. *Nat Commun.* 2022;13(1):5126. (*member of the investigative team cited in the appendix of the manuscript)

Non-peer reviewed scientific or medical publications/materials in print or other media

Proceedings of meetings or other non-peer reviewed research publications

1. De Graeve Diana, **Huybrechts K**, Dessers L, Heyrman J. Jan 1992. Laboratory testing in the general practitioner's office: Economic consequences, SESO Working Papers 1992004, University of Antwerp, Faculty of Business and Economics.
2. Mundkur ML, Franklin JM, Abdia Y, **Huybrechts KF**, Patorno E, Gagne JJ, Meyer TE, Staffa J, Bateman BT. Days' supply of initial opioid analgesic prescriptions and additional fills for acute pain conditions treated in the primary care setting - United States, 2014. *MMWR Morb Mortal Wkly Rep.* 2019;68(6):140-3.

Reviews, chapters, monographs and editorials

1. Caro JJ, **Huybrechts KF**. The cost-effectiveness of statin use. In: Gaw A, Packard CJ & Shepherd J, editors. *Statins: The HMG CoA Reductase Inhibitors in Perspective* (2nd ed). London: Martin Dunitz Publishers; 2004. pp. 213-27.
2. Horton DB, Hernandez-Diaz S, Lasky T, **Huybrechts KF**. Research on the effects of medications in pregnancy and in children. In: Strom BL, Kimmel SE, Hennessy S (editors). *Pharmacoepidemiology*. 6th edition. Wiley-Blackwell; 2019. pp. 524-60.
3. **Huybrechts KF**, Schneeweiss S. Studies relying on secondary data. In: Rothman KJ, Vanderweele T, Haneuse S, Lash TL. *Modern Epidemiology*. Fourth edition. Philadelphia: Lippincott Williams & Wilkins; 2021. pp. 247-62.
4. Schneeweiss S, **Huybrechts KF**. *Pharmacoepidemiology*. In: Rothman KJ, Vanderweele T, Haneuse S, Lash TL (editors). *Modern Epidemiology*. Fourth edition. Philadelphia: Lippincott Williams & Wilkins; 2021. pp. 1125-1145.
5. Horton DB, Hernandez-Diaz S, Lasky T, **Huybrechts KF**. Special applications of pharmacoepidemiology – Research on the effects of medications in pregnancy and in children. In Strom BL, Kimmel SE, Hennessy S (editors). *Textbook of Pharmacoepidemiology*, 3rd edition, John Wiley & Sons Ltd; 2022. pp. 387-463.
6. Wisner KL, Sit DKY, Miller ES, Monk C, Oberlander T, **Huybrechts KF**. Mental Health and Behavioral Disorders in Pregnancy. In: Landon M, Galan H, Jauniaux E, Driscoll D, Berghella V, Grobman W, Kilpatrick S, Cahill A (editors). *Gabbe's Obstetrics: Normal and Problem Pregnancies*. 9th edition. Elsevier (forthcoming)

Book

2021-2024 Rothman KJ, **Huybrechts KF**, Murray EJ, *Epidemiology: An Introduction*. 3rd edition. Oxford University Press, September 2024.

Letters to the Editor

1. Caro JJ, Xenakis JG, **Huybrechts KF**. Ignoring study design heterogeneity in meta-analyses [letter]. *Arch Intern Med.* 2006;166:2046.
2. **Huybrechts KF**, Palmsten K, Hernandez-Diaz S. Necessary exclusions to enhance validity of studies based on Medicaid claims data [letter]. *Ann Fam Med.* 2011;9:358.

Thesis

Huybrechts KF. Adverse health outcomes associated with psychotropic medication use in older nursing

home patients [dissertation]. Boston University School of Public Health; 2010.